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1 Introduction 
1.1 Background 
1.1.1 Therapeutic drug monitoring 
Pharmacokinetics and pharmacodynamics 
Pharmacological drugs and medicines to treat a wide variety of illnesses have been used since time 
immemorial. However, detailed understanding of the dose-response relationship between a drug and its 
effects arised in the 1960s for the first time [1].  
Effect and effectiveness of an administered drug is dependent from pharmacokinetics (PK) and 
pharmacodynamics (PD). Pharmacokinetics characterize all processes a drug passes though the 
human body. These include adsorption, distribution, metabolism and excretion (ADME). Consideration 
of following individual pharmacokinetic variables is decisive: 
• A: Knowledge of the correct time of administration, dosage and application type (e.g. oral or
subcutaneous) together with the bioavailability of a specific drug influence adsorption.
• D: Both, physicochemical properties and varying milieus between different compartments affect
distribution of a drug to its side of action, e.g. the epithelial fluid for pneumonia.
• M: Metabolism enzymatically alters drugs (e.g. by glucuronidation or sulphation) and thus first
activates, so-called pro-drugs, or commonly inactivates drugs before elimination.
• E: Excretion of a drug is dependent from its physicochemical properties, its previous distribution
in hydrophilic or lipophilic compartments and its metabolism.
Pharmacokinetics are balanced with pharmacodynamics: the doctrine of the interactions between drug 
and body. Drugs mainly interact through agonistic or antagonistic effects on receptors or receptor-like 
proteins, also including intracellular compounds (e.g. enzymes) within a body or microorganism. In the 
end, respective drug effects are dependent from related concentration levels. This relationship is 
commonly illustrated by a dose-response curve, where concentration levels are specified into sub-
therapeutic, therapeutic and toxic levels. Sub-therapeutic levels result in poor drug effectiveness, 
whereas toxic concentrations potentially induce adverse events. Consequently, adequate dosage is 
crucial to attain and maintain drug concentration within its therapeutic range, without the occurrence of 
relevant side effects.  
Accurate dose adjustment is both dependent from pharmacodynamics like drug target concentration 
and pharmacokinetics such as individual metabolism, in other words the PD/PK target. In particular, this 
applies to bacterial or fungal infections [2, 3].  
The PD/PK target of anti-infectives 
PK/PD target attainment is substantial to treat bacterial and fungal infections successfully. On the one 
hand, the pathogen species and potential resistance patterns contribute to microbial pharmacokinetics. 
On the other hand, the minimal inhibitory concentration (MIC) of a pathogen and the respective time- or 
dose-dependent susceptibility to anti-infectives are mandatory for the evaluation of pharmacodynamics. 
Equally, considering intra- and inter-individual pharmacokinetic variabilities such as altered metabolism 
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and clearance, inflammatory processes and co-medication along with pharmacogenomics (age, weight 
or gender) are decisive [4, 5].  
Above all, challenging pharmacokinetics emerge in critically ill patients: including altered distribution of 
drugs in third space fluids (e.g. edemas) due to organ dysfunction and increased vascular permeability, 
compromised metabolism and clearance through renal and hepatic impairment or life-supportive 
artificial organs such as extra corporal membrane oxygenation that potentially affect drug levels inside 
the patient.  
Detailed understanding of pharmacodynamics and pharmacokinetics result in pathogen- and patient-
dependent PD/PK targets and are consequently required for adequate therapeutic drug monitoring 
(TDM) [2, 6-8].  
Therapeutic drug monitoring in the clinical laboratory 
The determination of a specific drug concentration in body fluids, so-called therapeutic drug monitoring, 
primarily aims to improve dosage of drugs and therefore to attain PD/PK targets. Accordingly, the patient 
is protected against sub-therapeutic and toxic drug concentrations. In addition, TDM provides a broad 
range of other applications such as compliance controlling, prevention and identification of drug-drug 
interactions or causal analysis of therapy failure [3, 8-10]. 
Besides prevention and therapy of various diseases by analysis of endogenous and exogenous 
substances in body fluids, TDM became an emerging focus in clinical laboratories, recently. An 
indispensable aspect of TDM is the total turnaround time, the time that is required from sampling until 
the analytical result. Apart from the pre-analytical phase like sample handling, the analytical method 
implies a major variable of the total turnaround time. Analysis of complex matrices such as blood or 
urine requires analytical systems with high selectivity and in addition, sufficient sensitivity to quantify low 
concentrations of target substances. In combination with multi-analyte quantification, the ideal analytical 
method provides accurate results with short acquisition times [11-13].  
Almost every clinical laboratory is equipped with fully automatic analyzers. These immuno-photometric 
systems offer high throughput opportunities and therefore short turnaround times. However, the lack of 
multi-analyte assays and cross-reactivity between structurally related compounds represent major 
drawbacks of these systems. Indeed, auto-analyzers require marginal staff capacities, but individual 
assay development to comply clinics with innovative applications is barely practicable. Lastly, the lack 
of standardization still generates heterogeneous results between different systems and laboratories [13, 
14].  
In contrast, liquid chromatography mass spectrometry (LC-MS) bears the potential to overcome these 
drawbacks: a high level of selectivity plus sensitivity and the ability to develop multi-analyte assays in 
combination with individualized drug panels. Additionally, reliable quantification of structurally related 
compounds like isomers or metabolites as well as physicochemically diverse analytes is both feasible. 
Especially with respect to standardization, monitoring of inconsistent results is essential. Due to 
analytical metadata generated by the LC-MS system, respective results can be re-evaluated. To 
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summarize, LC-MS is an excellent quantitation method in the field of TDM but still poorly disseminated 
[15-17].  
Until now, main applications of LC-MS in clinical laboratories are TDM of antidepressants, antipsychotics 
or immunosuppressive drugs. However, an increasing number of studies report on inadequate standard 
dosage of anti-infectives, accordingly TDM of these drugs using LC-MS is a logical consequence [5, 6, 
18, 19]. 
 
1.1.2 Liquid chromatography mass spectrometry 
Since the 1970s high performance liquid chromatography (HPLC) is used in laboratories to separate 
and analyze various compounds in solutions and mixtures [20]. Depending on their polarity, the analytes 
show different retention times due to varying adsorption to the stationary phase and are accordingly 
separated [21, 22]. Then, quantification of the target analytes is performed by transferring the eluate to 
a detector such as a mass spectrometer (MS) coupled to the HPLC system. 
Tandem mass spectrometry 
The MS is equipped with an ion source, where the solvent is vaporized and the analytes are transferred 
into gas phase as positively or negatively charged ions. Within the MS, the ions are carried stepwise 
from atmospheric pressure to a vacuum before they reach the mass analyzer, which separates them by 
their specific mass-to-charge ratio (m/z). In clinical laboratories, almost exclusively triple quadrupole or 
tandem mass spectrometry (MS/MS) is applied so far. A quadrupole consists of four parallel metal rods 
arranged in a square with opposite rods having the same potential. This potential is generated by 
alternating and direct currents. As soon as a periodic voltage is applied to these quadrupole rods, the 
ions are subject to a constant alternation of repulsion and attraction. Hence, only ions with a specific 
m/z and therefore a stable path may pass through the quadrupole arrangement (see Figure 1) [23, 24].  
Figure 1: Schematic representation of a quadrupole analyzer. Only ions with a specific mass-to-charge 
ratio (m/z) are able to pass through the quadrupole (purple line). Other ions with an irregular trajectory 
hit the metal rods, are discharged and therefore removed (orange line). 
Tandem MS, also called triple quadrupole MS, combines three quadrupoles in serial arrangement. 
Within this setting, multiple-reaction monitoring (MRM) mode is often used for quantification due to its 
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unique selectivity and sensitivity: The first and third quadrupoles act as mass filters. Whereas the second 
quadrupole represents a collision cell. The ions that traverse the first quadrupole, so-called precursor 
ions, are further fragmented in this cell into product ions by collision with inert gas (e.g. nitrogen). Lastly, 
specific product ions are selected by the third quadrupole and are able to pass to the ion detector, e.g. 
a photomultiplier [20, 24]. 
High-resolution mass spectrometry 
A new type of mass analyzer is the Orbitrap-high-resolution mass spectrometer (HRMS). The Orbitrap-
HRMS consists of a central electrode and an outer electrode that is divided by a ceramic ring (see Figure 
2). Usage of a C-trap, which is a C-shaped quadrupole, is necessary to tangentially inject ions through 
high voltage pulses into the Orbitrap-HRMS [25]. An attracting electrostatic potential is applied to the 
central electrode inside the Orbitrap-HRMS, which counteracts the centrifugal force of the initial 
tangential velocity of the ions. The electrostatic field forces the ions to rotate around the central electrode 
with specific axial oscillations. The frequency of these axial oscillating ions is again dependent on their 
m/z, which is calculated using Fourier-transformation. Quantification based on frequencies generates 
high resolution and mass accuracy, which allows distinguishing between isobars without 
chromatographic separation. A distinctive characteristic of the Orbitrap-HRMS compared to MS/MS 
technology is its ability to act as mass analyzer and detector in combination. So far, Orbitrap-HRMS is 
predominantly used for analysis of proteins and metabolites or unknown screening [24, 26-28]. 
Figure 2: Schematic representation of an Orbitrap-HRMS mass analyzer. Ions are tangentially injected 
by the C-trap and begin to oscillate axially around the central electrode. The frequency of the ion 
oscillation is specific for their respective mass-to-charge ratio (m/z). 
Isotope dilution technique 
LC-MS applications for TDM mainly uses stable isotopically labeled internal standards (SIL-IS) to further 
improve its performance. Thereby, quantification is based on plotting the ratio of the analyte area to the 
SIL-IS area against respective concentrations. A SIL-IS differs in substitution of single atoms, typically 
exchange of hydrogen with deuterium or 12C atoms with 13C atoms, from the original analyte. 
Consequently both, analyte and SIL-IS, share the same physical and chemical properties and will 
behave almost identically regarding distribution within the matrix, retention time or ionization pattern. 
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Hence, usage of SIL-IS will correct variations during sample preparation or alterations inside the LC 
system. Furthermore, the suppression or enhancement of analyte ionization due to residual matrix 
components, so-called matrix effect, often compromises MS performance. Since analyte and SIL-IS 
share the same ionization pattern, usage of SIL-IS also fully compensates detrimental matrix effects 
[29-31].  
 
1.1.3 Anti-infective drug application in patients with severe infections 
Among any patient collective, intensive care unit (ICU) patients are at eminent risk to suffer from severe 
infections caused by invasive fungi or bacteria. The situation of ICU patients even exacerbates due to 
development of resistant bacterial and fungal strains [5, 6]. Extensive usage of antibiotics and 
antimycotics in agriculture and farming, inappropriate prescribing, missing identification of pathogens 
and resistance patterns leads to the emergence of antimicrobial resistance, which is even declared as 
one of the “ten threats to global health in 2019” by the World Health Organization [32]. In addition to 
their vulnerable health condition, altered pharmacokinetics in ICU patients through increased vascular 
permeability and volume of distribution, organ dysfunction and transplantation, extensive co-
medications and co-morbidities or extracorporeal therapies, as mentioned in section 1.1.1, facilitate 
invasion of pathogens and thus complicate PK/PD target attainment [33-36]. Treatment with sub-
therapeutic dosages, resulting from failed PK/PD targets, triggers resistance and increases the risk of a 
negative outcome, especially in critically ill. To improve anti-infective treatment and attain PK/PD targets, 
TDM is a powerful tool [8, 37].  
 
1.1.4 Aim and scope 
In this thesis, the transversal objective was the investigation of the potential of complex MS-methods for 
application in the field of therapeutic drug monitoring using both tandem MS and Orbitrap-HRMS 
technology. 
Besides analyte and technique specific requirements, methods intended for TDM application in clinical 
routine should comply with the following criteria: Practicability providing easy-to-use procedures and 
high-throughput as well as high sensitivity and selectivity for accurate quantification of target analyte at 
low concentrations in complex matrices. Furthermore, the capability of multi-analyte quantification in 
combination with wide dynamic ranges allows for broad performance spectra and quantitative working 
ranges covering sub-therapeutic up to toxic concentrations. Finally, method flexibility is crucial to 
integrate additional analytes for quantification and thus to provide innovative services. These method 
specifications for TDM in the clinical routine finally enable adequate control of serum levels, especially 
in critically ill patients.  
The aim of the first project was to develop and to study a reliable method for the quantification of six 
most widely used antibiotics in critically ill using tandem mass spectrometry. A main aspect and 
technicolgical challenge of this study was the establishment of wide dynamic ranges to determine any 
relevant antibiotic serum concentration. In addition, a video was published to test an innovative 
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publication format and therefore to increase dissemination towards scientific colleagues and clinical 
laboratories.  
The objective of the second project was to develop and to study a method to quantify the 11 most 
commonly used systemic antimycotics in ICU patients using high-resolution mass spectrometry. In this 
context, the broad m/z range of the physicochemically heterogeneous analyte panel required 
considerable efforts for accurate quantification. Moreover, a main goal was to evaluate suitability of high-
resolution mass spectrometry in clinical routine of small molecule TDM by comparison of a panel of 
leftover routine samples with an established LC-MS/MS method. 
 
1.2 Development and investigation of an isotope dilution LC-MS/MS method for therapeutic 
drug monitoring of antibiotics  
Clear recommendations for the TDM of antibiotics from different substance classes are published [8, 
36, 38]. Using LC-MS provides the ability to quantify analytes with different physicochemical properties 
in a single run and thus allows multi-analyte TDM. The beta-lactams cefepime, meropenem and 
piperacillin, the oxazolidinone linezolid, as well as the fluorochinolones ciprofloxacin and moxifloxacin 
are the most commonly used antibiotics in ICU. A major drawback of many analytical methods is the 
incomplete coverage of the clinically relevant range (sub-therapeutic and toxic concentrations) due to a 
complex combination of target measurement quantities [36, 39-42]. Despite these ambitious 
measurement quantities, broad calibration ranges in the original articles in this doctoral thesis were 
established to cover both peak levels, e.g. after bolus administration, and trough levels close to MIC of 
specific pathogens. Hence, measurements of concentrations from 0.05 mg/L ciprofloxacin to 400 mg/L 
piperacillin were practicable. 
An additional challenge of the method development was to optimize analyte extraction protocol in order 
to provide adequate recovery and reproducibility results for all analytes. Therefore, methanol, ethanol, 
dichloromethane, dimethyl sulfoxide, acetonitrile, acetone and tert-butylmethylether were tested in 
different compositions and volumes for protein precipitation. Finally, a combination of methanol and tert-
butylmethylether (90:10, v/v) was chosen for sample clean-up. Furthermore, samples were processed 
in cold environment whenever possible due to instability of piperacillin, meropenem and cefepime [43]. 
In the end, all analytes were chromatographically separated within 4 min, giving a total assay turnaround 
time of 25 min in order to provide short reporting times to the physicians. 
The method was also tested thoroughly for analyte selectivity. Even though tandem MS technology is 
highly selective, as described in section 1.1.2, interference with endogenous compounds from the 
specimen (the so-called matrix) and other exogenous interfering substances (e.g. patient medication 
and metabolites thereof) must be excluded during method validation. Especially, multimorbidity and 
polypharmacy introduce a high degree of complexity in the critically ill with the risk of unforeseen 
analytical interference. In addition, specimens showing interferences through hemolysate, bilirubin or 
lipids are common in clinical routine. Therefore, providing high selectivity is mandatory to obtain accurate 
results. For this purpose, blank specimens without the analytes in this study were investigated. To 
include the maximum amount of interfering elements, a highly diverse sample set was collected. The 
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sample set included various patient samples (both ICU and non-ICU) and samples spiked with 
hemolysate, bilirubin and lipids (HIL, hemolysis, icterus, lipemia). After thorough investigation, none of 
the samples showed interfering peaks at respective analytical retention times, so excellent method 
selectivity could be demonstrated. 
The method was validated according to the Guideline on bioanalytical method validation from the 
European Medicines Agency (EMA). Guidelines for LC-MS methods quantifying xenobiotics are lacking 
and therefore the EMA guideline is commonly used for LC-MS method implementation and validation 
[44]. 
The method was not only published in the Journal of pharmaceutical and biomedical analysis, but also 
in the Journal of visualized experiments using the exact method protocol, which allows method-transfer 
with a video step-by-step guide. We decided to apply this innovative publication format to facilitate the 
dissemination of this technically demanding methodology. 
To these publications, the author of this doctoral thesis contributed substantially in the processes of 
conceptualization, method development, formal evaluation and analysis of data, writing, review and 
editing. 
 
1.3 Development and investigation of an isotope dilution LC-Orbitrap-HRMS method for 
therapeutic drug monitoring of antimycotics  
Clinical relevance is also true for TDM of antimycotics. Adequate PK/PD target attainment equally leads 
to fewer side effects and development of resistances [5]. Azole antimycotics, echinocandins, 5-
flucytosine (a cytosine-analogue) and amphotericin b (a polyene) are a heterogeneous and 
physicochemically more diverse panel with an m/z range from 129 – 1270 compared to the previously 
addressed antibiotics (m/z 331 – 517). Accordingly, LC-MS is the predestined method for quantification 
of this disparate, multi-analyte panel.  
To achieve short turnaround times, online solid phase extraction using a turbulent flow extraction column 
was implemented for sample preparation: after the testing of several extraction columns with reversed 
phase properties, no adequate retention of the analyte 5-flucytosine could be achieved. Only, using an 
innovative extraction column with both reversed phase and ion exchange properties and mobile phases 
that were adapted to the necessary pH values, adequate retention of all analytes was possible. 
Applicability of clinical practice was further optimized using commercially available antimycotics TDM kit 
components. After protein precipitation by the manufacturer´s precipitation reagent and purification of 
the supernatant by the novel mixed-phase extraction column technology, the purified samples were 
separated within 4 min using an analytical C18 column and the eluent was transferred into the Orbitrap-
HRMS.  
Compared with precursor-to-product monitoring using MS/MS, Obritrap-HRMS detects non-fragmented 
precursor ions in full-scan mode. Selectivity of the Orbitrap-HRMS full-scan mode is ensured by high 
mass resolution and accuracy due to quantification based on frequencies, as described in section 1.1.2. 
However, this principle was examined by analysis of more than 60 samples from ICU, non-ICU and TDM 
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panel QCs. No interfering peaks at analyte retention times could be detected after detailed investigation. 
Hence, selectivity of Orbitrap-HRMS using full-scan mode could be verified. 
The method was comprehensively validated according to the Guideline on bioanalytical method 
validation from the European Medicines Agency (EMA) [38]. In addition, usage of three calibrators, as 
suggested by the kit manufacturer was compared to an extended range of six calibrators, as the EMA 
guideline recommends. The results of the quantifications were consistent using both a three-point and 
six-point calibration assay. Therefore, usage of only three calibrators is practicable in clinical routine. 
However, awareness is mandatory that invalid calibration curves may be generated using only three 
calibrators, if one calibrator fails the quality criteria (e.g. deviation from the nominal concentration ≥ 
15%). 
A main objective of this doctoral thesis was to evaluate whether Orbitrap-HRMS is suitable for TDM of 
small molecules, like the well-established MS/MS technology. So far, main application of Orbitrap-HRMS 
is predominantly in the field of proteomics and metabolomics, as mentioned in section 1.1.2. Evaluation 
of Orbitrap-HRMS suitability for small molecule TDM was executed by quantification of leftover routine 
samples (containing itraconazole, OH-itraconazole, posaconazole and voriconazole) with a clinical 
routine LC-MS/MS method against the herein validated LC-Orbitrap-HRMS method. The results of both 
methods showed good correlation, regardless of using three or six calibrators. Furthermore, 
development of both, antibiotic and antimycotic TDM assays, revealed practicability of Orbitrap-HRMS 
besides MS/MS, especially with respect to efforts in system and tuning set-up, where Orbitrap-HRMS 
showed rapid feasibility. Additionally, time-consuming product ion search was dispensable due to usage 
of full-scan mode without loss of selectivity. On the other hand, the significant higher costs of an Orbitrap-
HRMS system have to be taken into account. Purchasing this kind of system may be an economic 
challenge in a clinical laboratory, especially in cases without scientific scope besides the routine TDM. 
In those situations, usage of MS/MS is clearly superior, as these systems comply with any routine 
requirements and are considerably less expensive. 
Hence, the capability of Orbitrap-HRMS for development of efficient methods targeting low molecular 
weight TDM alongside MS/MS was found. Thus, the extension of the Orbitrap-HRMS application in the 
field of TDM is justified. In addition, Orbitrap-HRMS technology allows for known and unknown screening 
or acquisition of metabolomic data in any specimen as well as retrospective sample analysis due to full-
scan mode with the result of facultative information and broadened application [28]. 
The doctoral candidate was responsible for all parts of the project and publication respectively: project 
planning and conceptualization, experimental laboratory work (e.g. LC-MS method development in 
combination with all aspects of sample preparation), planning and realization of the method validation 
protocol, measurements, data analysis and evaluation, manuscript writing and submission. 
 
1.4 Summary / Zusammenfassung 
Severe infections caused by bacteria or fungi are a leading cause of morbidity and mortality in critically 
ill patients. Therapeutic drug monitoring is of uppermost importance for PK/PD target attainment and 
therapy control. Due to the structurally diverse antibiotic and antimycotic panels and the analytical 
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advantages over established immuno-photometric analyzers, LC-MS is the most suitable quantification 
technology, allowing both high selectivity and sensitivity. 
In the first project of this doctoral thesis, an isotope dilution LC-MS/MS method was developed for 
quantification of six commonly used antibiotics in intensive care units. By protein precipitation with 
methanol and tert-butylmethylether (90:10, v/v) and rapid analytical separation within 4 min, a results-
turnaround time of 25 min was achieved. In addition, wide dynamic ranges were established to cover 
serum concentrations from sub-therapeutic up to toxic. Good clinical suitability for everyday use as well 
as reliable and robust quantification of antibiotics was demonstrated by comprehensive validation.  
The second project aimed at developing an isotope dilution LC- Orbitrap-HRMS method for 
quantification of eleven systemic antimycotics. By using a mixed-mode extraction column and 
subsequent analytical separation, a very clean sample was obtained before injection into the Orbitrap-
HRMS system. The method provided accurate quantification of the heterogeneous analyte panel with 
broad m/z range. After validation, the method was compared to a routinely established LC-MS/MS 
method. This evaluation showed that novel Orbitrap-HRMS technology is appropriate for TDM of small 
molecules besides MS/MS.  
Considering their respective assets and drawbacks, both MS/MS and Orbitrap-HRMS technologies 
enable the development of particularly efficient and reliable methods for small molecule TDM. 
 
Eine der Hauptursachen für Morbidität und Mortalität bei kritisch kranken Patienten sind 
schwerwiegende bakterielle oder mykotische Infektionen. Um definierte PK/PD-Zielspiegel zu erreichen 
und Therapiekontrolle zu ermöglichen ist das therapeutische Drug-Monitoring von entscheidender 
Bedeutung. Durch die strukturelle Vielfalt von Antibiotika und Antimykotika sowie der analytischen 
Vorteile gegenüber etablierten immuno-photometrischen Messgeräten, ist die LC-MS die geeignetste 
Quantifizierungsmethode, die neben hoher Selektivität auch hohe Empfindlichkeit gewährleistet. 
Im ersten Teil dieser Doktorarbeit wurde eine Isotopenverdünnungsmethode mittels LC-MS/MS 
entwickelt, die zur Quantifizierung von sechs, häufig auf Intensivstationen verwendeten Antibiotika, 
diente. Nach Proteinfällung mit Methanol und tert-Butylmethylether (90:10, v/v) und anschließender 
analytischer Trennung innerhalb von 4 min wurde eine effektive Gesamt-Turnaround Zeit von 25 min 
erreicht. Des Weiteren wurden breite dynamische Bereiche etabliert, um sowohl subtherapeutische als 
auch toxische Serumkonzentrationen zu erfassen. Gute klinische Alltagstauglichkeit sowie zuverlässige 
und robuste Quantifizierung der Antibiotika wurde hierbei im Rahmen einer umfassenden Validierung 
gezeigt. 
Der zweite Teil der Arbeit hatte ebenso die Entwicklung einer LC-MS-basierten 
Isotopenverdünnungsmethode zum Ziel, jedoch unter Verwendung eines Orbitrap-HRMS zur 
Quantifizierung von 11 systemischen Antimykotika. Durch den Einsatz einer „Mixed-Mode“ 
Extraktionssäule konnte nach darauffolgender analytischer Trennung ein sauberes Eluat gewonnen 
werden, welches dann zum Orbitrap-HRMS weitergeleitet wurde. Die Methode ermöglichte die exakte 
Quantifizierung aller heterogenen Analyten, die eine breite m/z-Verteilung aufwiesen. Im Rahmen der 
Validierung wurde die Methode mit einer routinemäßig etablierten LC-MS/MS-Methode verglichen. Die 
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Auswertung ergab, dass die neuartige Orbitrap-HRMS-Technologie für das therapeutische Drug-
Monitoring von kleinen Molekülen ebenso geeignet ist wie die MS/MS.   
Unter Berücksichtigung ihrer jeweiligen Vor- und Nachteile erlauben sowohl MS/MS- als auch Orbitrap-
HRMS-Technologien die Entwicklung besonders effizienter und zuverlässiger Methoden für das TDM 
von kleinen Molekülen. 
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a  b  s  t  r  a  c  t
The  aim  of  the  current  study  was  to develop  and  validate  a robust  multi-analyte  high  performance
liquid  chromatography  tandem  mass  spectrometry  (HPLC–MS/MS)  method  for simultaneous  quantifi-
cation  of cefepime,  meropenem,  ciprofloxacin,  moxifloxacin,  linezolid  and piperacillin,  which  are  the
most  commonly  used  antibiotics  in  intensive  care  units.
Sample clean-up  included  a protein  precipitation  protocol,  followed  by chromatographic  separation  on
a  C8 reverse  phase  HPLC  column  within  4 min,  using  a formic  acid-ammonium  formiate  methanol  step-
elution  gradient.  All  compounds  were  detected  with electrospray  ionization  (ESI+)  mass  spectrometry
in  multiple  reaction  time  monitoring.  The  method  was validated  according  to  the  protocol  from  the
European  Medicines  Agency  and  was  thoroughly  evaluated  for interferences  and  quantification  linearity.
Linear  relationships  between  peak  area  responses  and  drug  concentrations  were  obtained  in the
range  of 0.25–200  mg/l  for  cefepime,  0.25–120  mg/l  for meropenem,  0.05–10  mg/l  for  ciprofloxacin,
0.125–10  mg/l  for moxifloxacin,  0.125–50  mg/l  for  linezolid  and  0.5–400  mg/l  for  piperacillin  with an
R2 > 0.997.  Imprecision  and  inaccuracy  values  (both  intra-  and  inter-assay)  were  ≤  6.8%  and  ≤10.9%
for  all  analytes  in  quality  control  samples,  respectively.  The  assay  proved  to  be selective  for  the  study
antibiotics,  and  the  internal  standards  consistently  compensated  for matrix  effects.
The  described  simple  and  reliable  HPLC–MS/MS  assay  is a powerful  tool  for routine  TDM  of cefepime,
meropenem,  ciprofloxacin,  moxifloxacin,  linezolid  and  piperacillin  in human  serum  in clinical  laborato-
ries.  With  a  total  process  time  of approximately  30 min,  it allows  for accurate  and  selective  quantification
up  to the  expected  pharmacokinetic  peak  concentrations
©  2018  Published  by  Elsevier  B.V.. Introduction
Severe infection is an important source of morbidity and mortal-
ty in intensive care unit (ICU) patients [1]. Timely administration
f the antimicrobial substance with appropriate drug level and
athogen spectrum is of paramount importance for clinical success
2]. Achieving sufficiently high concentration levels is also relevant
or preventing the development of antimicrobial resistance [3].
Antimicrobial  therapy is usually based on standard dosing
rotocols. However, numerous studies point out that hetero-
eneous patient populations with growing complexity have
harmacokinetics that are subject to substantial inter-individual
∗ Corresponding  author at: Department of Laboratory Medicine, Marchioninis-
rasse  15, 81377, Munich, Germany.
E-mail  address: Michael.Paal@med.uni-muenchen.de (M.  Paal).
ttps://doi.org/10.1016/j.jpba.2018.01.031
731-7085/© 2018 Published by Elsevier B.V.variation (e.g. the critically ill, obese, elderly, patients with severe
comorbidities) [4–8]. Accordingly, traditional antibiotic dosing
strategies are becoming increasingly problematic, as the phar-
macokinetic/pharmacodynamic (PK/PD) target that is required for
effective treatment of severe infections may  not be reached [9–11].
Especially the prediction of drug exposure of hydrophilic antibiotics
(e.g. ß-lactams) in ICU patients remains challenging, due to patho-
physiological changes in distribution und drug clearance [12,13].
However, broad-spectrum antibiotics, such as piperacillin (usually
prescribed with tazobactam) and meropenem, are widely used in
intensive care [14,15]. For both substances inadequate PK/PD target
attainments have been reported in several studies [9,16,17].
An  individualized way to overcome variability and underdos-
ing, is guided treatment with therapeutic drug monitoring (TDM)
in an attempt to both maximize the antimicrobial efficacy and also
to minimize toxic side effects, consequently improving the gen-
eral clinical outcome from infections [18]. For the implementation
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f local and national antibiotic stewardship strategies there is an
ver-increasing demand for antibiotic TDM [19], which has there-
ore received a lot of attention in recent years [20–24]. In clinics,
DM has been routinely used in the past for glycopeptide antibiotics
nd aminoglycosides, as these antibiotics have a narrow therapeu-
ic index [18,25]. As commercial procedures are not available for
eneric antibiotic TDM in clinical routine, quantification methods
or other antibiotic classes have to be developed and be validated
n-house. To find application in clinics, TDM methods have to be
obust and convenient, allowing for easy sample preparation, short
ssay run times and proper quantification in the clinical relevant
ange.
Various methods for multi-analyte antibiotic TDM have been
ublished in the past [26–37]. Among these, several high-
erformance liquid chromatography (HPLC) procedures were
ombined with UV-detection [26–29]. These methods, however
sually have rather long run times, low detection capabilities and
hey are not very selective, leading to the risk of interferences
ith co-medications and endogenous substances. By comparison,
hromatographic separation coupled with tandem mass spectrom-
try (MS/MS) has greater detection capabilities and an improved
electivity [31–37]. Many of these published methods quantify
tructurally related substances from one antibiotic class only, espe-
ially ß-lactam antibiotics [38]. However, a TDM approach that
nalyzes the most relevant antibiotics from different classes can
e more efficient in terms of high sample throughput and costs. It
ust be emphasized that several methods described in literature
ave rather narrow calibration ranges, which do not allow to mea-
ure peak concentrations and toxic levels without the requirement
f sample dilution.
Summarized, there is a great demand for antibiotic TDM in
any medical facilities on a day-to-day basis, allowing quick adap-
ion of dosing with least possible turn-around times. Therefore,
he purpose of the current work was to establish a simple and
eliable multi-analyte LC–MS/MS method for quantification of the
ost utilized antibiotics in critical care that could be established
n mass spectrometry laboratories with minimal expense. The
ssay required a broad concentration range, with a lower limit of
uantification (LLOQ) as close to the minimal inhibitory concen-
rations (MIC) of susceptible microorganism and an upper limit of
uantification (ULOQ) exceeding expected pharmacokinetic peak
oncentrations that may  be obtained after bolus administration.
.  Materials and methods
.1.  Chemicals and reagents
A  drug free serum pool was obtained from the blood donation
enter of the Bavarian Red Cross (Munich, Germany). Antibiotics
efepime hydrochloride, meropenem trihydrate, ciprofloxacin,
oxifloxacin hydrochloride and piperacillin sodium salt, were
rovided by Sigma-Aldrich (St. Louis, Missouri, USA). Linezolid,
nd isotope-labelled antibiotics meropenem-D6, ciprofloxacin-D8,
oxifloxacin hydrochloride-13C1D3, linezolid-D3, and piperacillin-
5 were obtained from Toronto research chemicals (Toronto,
ntario, Canada). Isotope-labelled cefepime-13C12D3 sulfate was
rom Alsachim (Straßbourg, Grand Est, France). HPLC-grade water,
ethanol, acetonitrile was from Baker (Jackson, Tennessee, USA),
ormic acid from Biosolve (Dieuze, Grand Est, France), ammo-
ium formate from Sigma-Aldrich (St. Louis, Missouri, USA). Drugs
sed for the interference studies were obtained from Roche
Basel, Switzerland), Chromsystems (Gräfeling, Germany), Recipe
Munich, Germany) and Invicon (Munich, Germany). All used
hemicals were of the highest purity available from the commercial
uppliers.iomedical Analysis 152 (2018) 102–110 103
2.2. Calibrators samples, quality control samples and internal
standards
Stock  solutions and corresponding ten-fold spike solutions for
the antibiotics cefepime hydrochloride, meropenem trihydrate,
linezolid and piperacillin sodium salt were prepared by separate
weighting in a methanol-water solution (25:75, v/v). Stock solu-
tions of moxifloxacin hydrochloride and ciprofloxacin were also
prepared in a methanol-water solution (25:75, v/v), however with
the addition of 20 mM acetate. These stock solution volumes were
then combined to yield both the spike solutions for the calibra-
tors and quality controls (QC). To preserve the physiological matrix,
only one volume of 10x spike solution was admixed with nine vol-
umes of drug free serum. A total of eight calibration standards
and four quality control samples was prepared (see Table 1 for
exact concentrations). After preparation, stock and spike solutions,
calibrators and QC-samples were aliquoted and kept at −80 ◦C.
The nominal concentrations of QC-samples were verified by com-
parative measurements with independent mono-analyte specific
LC–MS/MS methods.
Stock  solutions of internal standard (IS) with 1 mg/ml con-
centration were prepared by diluting cefepime-13C12D3 sulfate
in distilled water; meropenem-D6, linezolid-D3 and piperacillin-
D5 in a methanol-water solution (50:50, v/v); ciprofloxacin-D8
in a methanol-water solution (50:50, v/v) including 20 mM
acetate and moxifloxacin hydrochloride-13C1D3 in distilled water
with 20 mM acetate. The internal standard stock solutions were
then combined in a methanol-water mix  (25:75, v/v) to pre-
pare a IS standard mixture containing 30 mg/l cefepime-13C12D3,
25 mg/l meropenem-D6, 2.5 mg/l ciprofloxacin-D8, 5 mg/l mox-
ifloxacin hydrochloride-13C1D3, 5 mg/l linezolid-D3 and 25 mg/l
piperacillin-D5. Internal standard stock solutions and the mixture
were temporarily stored at −20 ◦C until use.
2.3. Method development
Method  development was initiated with a Reprosil PUR ODS-
3 (100 mm × 2.1 mm,  5 m particle size) column (Dr. Maisch,
Ammerbuch-Entringen, Germany) using mobile phases A 10 mM
ammonium formate in water-formic acid (99.9:0.1, v/v) and B
acetonitrile. To establish an efficient extraction method for the
antibiotics in this study, protein precipitants in different combi-
nations were tested, including methanol, acetonitrile, dimethyl
sulfoxide, methyl-tert-butyl ether, acetone, isopropanol, zinc-
sulfate and trichloroacetic acid. The best results with regard
do extraction yields and reproducibility were obtained with a
methanol – methyl-tert-butyl ether (90:10, v/v) precipitation
reagent.
To improve chromatography, various reverse phase C8 and
C18 columns were tested with different mobile phases and gra-
dients. Satisfactory chromatographic separation was  obtained
within 4 min  using a Fortis 3 m C8 reverse phase column
(100 mm × 2.1 mm,  3 m particle size) (Neston, Cheshire, UK)
selecting the mobile phases A 10 mM ammonium formiate in
water-formic acid (99.9:0.1, v/v) and B methanol for a step-elution
chromatographic protocol. Injecting varying volumes of processed
QC A and D samples, identical responses (ratio of peak area ana-
lyte/peak area IS) were obtained for meropenem, moxifloxacin,
piperacillin within 3–30 l and for cefepime, ciprofloxacin, line-
zolid, within 15–50 l, respectively.
2.4. Sample preparationFirst,  100 l of either calibrator, QC or patient serum samples
were mixed with 25 l of the internal standard mixture in 1.5 ml
polypropylene cups (Eppendorf, Hamburg, Germany) for 5 min  at
13
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Table 1
Concentrations of calibrators and quality controls for the study antibiotics.
Analyte Calibration standards (mg/l) Quality controls (mg/l)
1 2 3 4 5 6 7 A B C D
Cefepime 0.25 0.75 2.5 10.0 50.0 125.0 200.0 0.75 50.0 100.0 150.0
Meropenem  0.25 0.75 2.50 10.0 40.00 80.0 120.0 0.75 30.0 60.0 90.0
Ciprofloxacin 0.05 0.1 0.3 1.0 3.0 6.5 10.0 0.150 2.5 5.0 7.5
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Moxifloxacin  0.125 0.25 0.75 2.0 5.0 
Linezolid  0.125 0.25 0.75 3.0 12.5 
Piperacillin  0.5 1.5 6.0 25.0 100.0
oom temperature using a vortex shaker (Eppendorf, Hamburg,
ermany). 150 l methanol – methyl-tert-butyl ether precipitation
olution (90:10, v/v) were added, followed by shaking for another
 min. After centrifugation at 20.000g for 10 min  at 4 ◦C, 75 l super-
atant were diluted 1:3 with HPLC grade water in a glass vial with
icroinsert that was then loaded to an autosampler (10 ◦C sample
ooling, ±5 ◦C) ready for injection.
.5.  HPLC conditions
Chromatography was performed on a Waters 2795 Alliance HT
PLC system that was coupled to a Waters Quattro micro API Tan-
em Quadrupole System (Waters, Milford, Massachusetts, USA).
ontrol of all system components and monitoring of the chro-
atographic run was performed with the Mass Lynx V4.1 software
Waters, Milford, Massachusetts, USA).
Chromatographic separation was performed with a total run
ime of 4 min  using a Fortis 3 m C8 reverse phase column (100 mm
 2.1 mm)  with a 3 m particle (Fortis, Cheshire, UK) and a
 m pre-column filter (Chromsystems, Gräfeling, Germany). The
olumn chamber was held at 30 ◦C. Mobile phases A 10 mM ammo-
ium formiate in water-formic acid (99.9:0.1, v/v) and B methanol,
ere delivered at a flow rate of 0.5 ml/min in step dilution mode.
tarting at 7% B for 0.1 min, mobile phase B was suddenly increased
o 65% and held for another 0.5 min. Afterwards the column was
ashed with 95% B for 1.5 min  and finally re-equilibrated to start-
ng conditions for approximately 2 min  with 7% mobile phase B. The
eneric sample injection volume was 15 l in a 100 l loop (partial
oop filling mode, air prefill: pre- and post-sample 2.0 l). Reten-
ion times were: 1.66 min  for cefepime, 1.81 min  for meropenem,
.04 min  for ciprofloxacin, 2.16 min  for moxifloxacin, 2.31 min  for
inezolid and 2.38 for piperacillin. A typical MRM  chromatogram
or calibrator 3 is depicted in Fig. 1. Autosampler wash conditions
ere as follows: the wash solvent was methanol, the seal and purge
olvent a methanol-water-formic acid solution (7:92.9:0.1, v/v/v),
he wash sequence was: 1x purge-wash-purge with 600 l purge
olvent replacement volume.
.6. Mass spectrometry conditions
Electrospray ionization in the positive mode (ESI+) was  used
or all analytes with following ion source settings: capillary volt-
ge 1.5 kV; source temperature, 120 ◦C; desolvation temperature,
00 ◦C; desolvation gas flow rate, 600 l/h; RF lens voltage 0.1 V.
The best mass transition-specific parameters, including the col-
ision energy and cone voltage were manually tuned for each
ntibiotic substance and its corresponding internal standard by
nfusion of neat substance at 10 l/min. Quantifier and qualifier
roduct ions were selected for optimal mass spectrometry detec-
ion. Multiple reaction monitoring transitions (MRM)  for each
ntibiotic and internal standard (quantifier and qualifier) with the
orresponding cone voltage and collision energy are shown in
able 2. The dwell time was set to 80 ms  for each channel. Data7.5 10.0 0.375 2.5 5.0 7.5
27.5 50.0 0.375 12.5 25.0 37.5
225.0 400.0 1.5 100.0 200.0 300.0
evaluation  was  performed with the Waters QuanLynx 4.1 software
(Waters, Milford, Massachusetts, USA).
2.7. Method validation
Assay  validation was conducted according to the guideline
of bioanalytical method validation from the European Medicines
Agency (EMEA), 21 July 2011 [39]. The procedure was evaluated
in terms of limits of quantification, calibration curve, accuracy
and precision, carry-over, selectivity, dilution integrity, recovery,
matrix effect and stability. Further assay robustness experiments
were conducted, with regard to interference from drugs and
endogenous serum compounds, and linearity.
2.7.1. Limits of quantification
According  to the EMA  guideline the lower limit of quantifica-
tion (LLOQ) represents the lowest concentration of an analyte in a
sample that can be quantified reliably. The lowest calibrator with
an inter-day imprecision and inaccuracy both <20% and a signal to
noise ratio ≥ 5 is considered the LLOQ. Imprecision was  expressed
with the coefficient of variation (CV), inaccuracy with relative bias
(ı↓r)
Meeting the clinical requirements of antibiotic TDM, LLOQı́s
were  as close to the lowest minimal inhibitory concentrations (MIC)
of susceptible pathogens from the EUCAST breaking point tables
[40]. The upper limit of quantification (ULOQ) was defined as the
calibration standard with the highest concentration of analytes.
2.7.2.  Calibration curves
The  clinical relevant TDM range was  covered with seven calibra-
tors containing the antibiotics that were processed together with
a blank (without analyte and internal standard) and zero samples
(including the internal standard only). According to the EMA  guide-
lines back calculated concentrations of the calibration standards
including the ULOQ should be within ±15% of the nominal value,
except for the LLOQ for which it should be within ± 20%. The follow-
ing calibration model was used: curve type, linear; origin, included;
weighting function, 1/x; axis transformation, none.
2.7.3. Inaccuracy and imprecision
Inaccuracy  und imprecision was tested by replicate analysis
(n = 10 for intra-assay, n = 5 for inter-assay on five different days)
using four different QC-samples A-D and the LLOQ, covering low,
medium and high concentration levels. Acceptable criteria were
deviations of the CV and ır within ±15%, except ±20% for the lowest
calibrator. In addition, the total error was assessed in form of the rel-
ative root-mean-square-error (% RSME) that should also not exceed
15% according to the guidelines of the German Federal Medicine
Council (RiliBÄK) [41]. The RMSE was  calculated as follows:%RMSE =
√∑n
i=1(i−)
2
n

14
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Fig. 1. Multiple reaction monitoring (MRM)  chromatograms of analytes with calibrator 3 concentrations. Analytic retention times are given in minutes.
Table 2
Mass  spectrometry parameters: multiple reaction monitoring transitions with parent and daughter ions for quantifier and qualifier.
Analyte Rt (min) Quantifier Qualifier
Parent (m/z) Daughter (m/z) CV (kV) CE (eV) Parent (m/z) Daughter (m/z) CV (kV) CE (eV)
Cefepime 1.66 481.0 167.0 20 22 481.0 395.7 20 13
Meropenem  1.81 384.1 114.0 20 25 384.1 141.0 20 16
Ciprofloxacin 2.04 332.0 231.0 30 35 332.0 245.0 30 25
Moxifloxacin  2.15 402.0 261.0 25 27 402.0 383.9 25 25
Linezolid  2.31 338.0 235.0 30 22 338.0 296.0 30 19
Piperacillin  2.38 518.0 143.0 25 20 518.0 358.9 25 10
Cefepime-13C12D3 1.66 485.1 167.1 20 22 485.1 400.0 20 13
Meropenem-D6 1.81 390.1 114.0 20 25 390.1 147.2 20 16
Ciprofloxacin-D8 2.04 340.1 235.1 30 35 340.1 249.3 30 25
Moxifloxacin- 13C1D3 2.15 406.1 265.1 25 27 406.1 388.0 25 25
Linezolid-D 2.31 341.1 235.1 30 22 341.1 297.1 30 19
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Piperacillin-D5 2.38 523.1 148.2 
etention time, RT; cone voltage, CV; collision energy, CE.
here i is the measured value of a sample that is compared to the
arget nominal value .
.7.4.  Carry-over
To  test for carry-over, blank samples were injected after the
ighest calibration sample (the ULOQ). According to the EMA  guide-
ine the peak area in blank samples following the ULOQ should not
xceed 20% of the peak area at the LLOQ and 5% of the peak area
f the internal standard. In addition the carry-over was  assessed
njecting the ULOQ twice, followed by three injections of the LLOQ
nd quantifying the carry-over ratio with following formula using
he peak area response signal [42]:arry  − over % = [ (LLOQ#1 − LLOQ#3)
(ULOQ#2 − LLOQ#3)
]  × 100
here the symbol # refers to the injection number.20 523.1 364.1 25 10
2.7.5. Selectivity
Selectivity was tested by spiking drug-free patient serum sam-
ples with varying degree of hemolysis, icterus and lipemia (HIL)
with the antibiotics in this study and quantifying the concentration
to be expected (n = 5). In addition, ten different serum samples were
used from both non-ICU and ICU patients (n = 20) not treated with
the antibiotics in this study, but receiving a broad range of other
drugs that were maintained in their respective therapeutic range.
Medications included other antimicrobials, psychotropic drugs,
antihypertensives, diuretics, cardiac drugs, anti-inflammatories,
analgesics and many other pharmaceutical drugs. Quality controls
from various routine TDM panels in our laboratory were also tested
for any interference. The substances investigated and their con-
centrations tested are given in the Supplemental Data, Table 1 and
2.
In accordance with the EMA  guideline, the absence of interfering
components is accepted when the response of an antibiotic and its
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tandard is <20% of the LLOQ for the analyte and <5% for the internal
tandard at the analytic retention time.
.7.6. Dilution integrity
Dilution  integrity was tested to ensure that analyte concentra-
ions above the ULOQ in real samples (e.g. reaching toxic levels)
ould produce original concentrations by back calculation. Antibi-
tics with 75% and twice the ULOQ concentration were spiked to
rug-free sera on two separate days, including hemolytic, lipemic
nd icteric (HIL) patient specimen (n = 5) for each concentration
ested. Following serial dilution with distilled water (1:2, 1:3, 1:5),
amples were prepared as described above and the initial concen-
ration determined. According to the EMA  guideline imprecision
nd inaccuracy should not exceed ±15%.
.7.7. Matrix effects and recovery
Ion suppression and matrix effects were evaluated with post-
olumn infusion experiments using neat calibrator 7 spike solution
n methanol-water [25/75 (v/v)] with a flow rate of 10 l/min.
Internal standard (IS) normalized matrix effects and the recov-
ries were examined according to the EMA  guideline using three
ample sets that had identical final analyte and internal stan-
ard concentrations. Antibiotic-free normal and hemolytic, icteric,
ipemic (HIL) patient sera (n = 6) were spiked before (set B) and after
ample preparation (set C) with low (3× LLOQ, 20% ULOQ) and high
ntibiotic concentrations (75% ULOQ) on three separate days and
eak areas compared to ones derived from neat antibiotic samples
n aqueous solution (set A). IS were added at the same stage to the
pecimen as the antibiotics.
Matrix  effects are defined as the ratio of the peak area of antibi-
tics spiked after extraction (presence of matrix) to the peak area of
eat analyte solution (absence of matrix). Since the internal stan-
ard is also affected by matrix effects, an IS normalized matrix
actor was calculated as the ratio of the matrix effect of a spe-
ific analyte and the matrix effect of the corresponding internal
tandard. According to the EMA  guideline both the coefficient of
ariation for the IS normalized matrix effect and the CV among
he concentrations should not exceed 15%. The recovery is defined
s the mean ratio between the peak area of the analyte spiked
efore extraction and the corresponding peak area of antibiotics
piked after extraction. According to the CLSI-IFCC-guideline [43]
eviations of the mean value should be ≤15%.
.7.8. Stability experiments
Stability  experiments were performed with quality control sam-
les QC B and QC D that were stored up to 6 h at RT, 24 h at 4 ◦C and
4 days at −20 ◦C. On-instrument stability of processed samples on
he autosampler was also tested for 24 h. Freeze and thaw stabil-
ty (–80 ◦C and RT, freeze time ≥12 h) of analyte in matrix was also
ested. According to the EMA  decreases in nominal concentrations
15% when compared to fresh counterparts that were immediately
nalyzed after preparation were considered relevant. In accordance
ith the EMA  protocol no long-term stability experiments were
erformed as pre-analytical long-term stability at −80 ◦C has been
ddressed in previous works [44,45].
. Results
.1. Method validation
.1.1.  Limits of quantification
Each  lowest calibrator concentration of the antibiotics in this
tudy fulfilled the EMA  criteria of the LLOQ with an (both intra- and
nter-assay) imprecision, inaccuracy and RSME of ≤12.5%, ≤9.6%
nd ≤11.2% (summarized in Table 3). All analyte signals of the LLOQiomedical Analysis 152 (2018) 102–110
were  at least ≥ × 30 the signal of blank samples at corresponding
antibiotic retention times.
3.1.2.  Calibration curves
A  linear regression model using weighting factor of 1/X was used
for antibiotic quantification using seven calibrators. The method
was linear over the whole concentration range with R2 ≥0.997 for
all antibiotics in this study.
3.1.3.  Inaccuracy and imprecision
The  data for intra- and inter-day inaccuracy and imprecision and
the relative root-mean-square-error is summarized in Table 3. The
coefficient of variation (CV), relative bias (ır) and RSME estimated at
four concentrations with quality controls A–D never exceeded 6.8%,
10.8% and 10.9% in the validated concentration range, respectively.
3.1.4. Carry-over
Initially, the peak-area at the retention times of ciprofloxacin
and moxifloxacin in blank calibration samples (without internal
standards and analyte) after measurement of the highest calibrator
considerably exceeded the criteria proposed by the EMA. Respec-
tive percentage carry-over ratios calculated according to Haeckel
[42] were 0.98% for ciprofloxacin and 1.90% for moxifloxacin. Var-
ious strategies were employed to reduce the HPLC carry-over,
including changes of the rinsing solution and the wash program
[46]. Acidifying the purge solution with 0.1% formic acid and using
a purge-wash-purge sequence considerably reduced the autosam-
pler carry-over of the fluorchinolones.
Peak-areas  observed in blank calibration samples after mea-
surement of the highest calibrator were accordingly ≤5.5%, ≤4.5%,
≤26.0%, ≤9.6%, ≤ 4.9.% and ≤ 19.4% of the LLOQ for cefepime,
meropenem, ciprofloxacin, moxifloxacin, linezolid and piperacillin.
The peak-area of the respective internal standard did not exceed
5%. The percental carry-over ratio calculated according to Haeckel
[42] was ≤0.03%, ≤0.03%, ≤0.21%, ≤0.18%, ≤0.02% and ≤0.07% for
cefepime, meropenem, ciprofloxacin, moxifloxacin, linezolid and
piperacillin. Although pH alterations and different additives in the
wash and purge buffer were tested, the carry-over could not further
be reduced for the fluorchinolone ciprofloxacin.
3.1.5. Selectivity
Quantification of spiked patient specimen (n = 5) was  not dis-
turbed by hemolysis, icterus and lipemia (HIL) as the quantified
concentrations to be expected were 95.9–105.2%. None of the
investigated substances, such as other antimicrobials, psychotropic
drugs, cardiac drugs, analgesics, immunosuppressants (for further
detail see Supplemental Data, Table 1) and none of the compounds
in non-ICU and ICU patient sera (n = 20) were found to interfere
with the quantification of the antibiotics in this study (see Supple-
mental Data, Table 2). For all samples tested no interfering peaks
were present. Responses at the retention times were ≤7.9%, ≤4.0%,
≤10.2%, ≤3.3%, ≤0.6%, ≤6.6% of the LLOQ for cefepime, meropenem,
ciprofloxacin, moxifloxacin, linezolid, piperacillin and ≤1% for all
internal standards.
3.1.6.  Dilution integrity
Inaccuracy  and imprecision values for HIL sample dilution
integrity are summarized in Table 4). They were found to be ≤13.7%
and ≤9.1% for an initial concentration of 75% of the ULOQ (n = 5),
and ≤13.8% and ≤8.4% for an initial concentration twice the ULOQ
(n = 5), respectively.3.1.7. Matrix effects and recovery
Post-column infusion experiments did not indicate relevant ion
suppressions at the expected retention time of each analyte (see
Fig. 2 in the online Data Supplement).
16
M. Paal et al. / Journal of Pharmaceutical and Biomedical Analysis 152 (2018) 102–110 107
Table  3
Intra-day (n = 10) and inter-day (n = 5) inaccuracy and imprecision obtained from measurement of quality control (A–D) and LLOQ (calibrator 1) samples.
Analyte QC A QC B QC C QC D LLOQ
Inter-assay Intra-assay Inter-assay Intra-assay Inter-assay Intra-assay Inter-assay Intra-assay Inter-assay Inter-assay
Cefepime
x̄ (mg/l) 0.78 0.79 51.66 53.8 99.22 100.4 137.36 146.9 0.25 0.24
CV (%) 5.6 4.8 3.9 4.0 4.5 5.7 3.4 6.8 8.1 12.5
r (%) 4.4 4.8 3.3 7.7 0.8 0.4 8.4 2.1 0.4 2.4
RSME (%) 7.1 6.7 5.1 8.7 4.3 5.3 8.9 6.5 4.7 11.2
Meropenem
x̄ (mg/l) 0.72 0.72 31.49 31.54 55.47 56.31 83.40 90.35 0.26 0.25
CV (%) 3.5 6.5 3.2 3.9 2.8 2.6 2.2 4.8 7.1 4.5
r (%) 3.84 3.4 5.0 5.1 7.5 6.1 7.3 0.4 4.4 1.6
RSME (%) 4.9 6.7 5.9 6.4 8.0 6.5 7.6 4.5 8.0 4.4
Ciprofloxacin
x̄ (mg/l) 0.15 0.15 2.56 2.56 4.94 4.90 7.32 7.20 0.05 0.05
CV (%) 5.0 3.8 2.9 4.9 2.4 2.3 3.6 3.0 3.7 4.5
r (%) 0.7 0.0 2.4 2.4 1.3 1.9 2.5 4.0 3.0 4.0
RSME (%) 4.7 3.6 3.7 5.2 2.5 2.9 4.1 4.8 4.5 4.8
Moxifloxacin
x̄ (mg/l) 0.35 0.37 2.57 2.63 4.68 4.95 6.69 7.38 0.11 0.13
CV (%) 2.3 4.7 3.7 3.5 3.4 3.1 1.8 4.1 4.3 3.5
r (%) 6.7 1.3 2.6 5.2 6.5 0.9 10.8 1.5 9.6 2.4
RSME (%) 6.9 4.5 4.4 6.2 7.2 3.0 10.9 4.1 10.3 4.0
Linezolid
x̄ (mg/l) 0.37 0.37 11.94 12.73 23.74 24.55 34.12 35.74 0.12 0.13
CV (%) 4.4 3.8 2.4 3.5 1.7 3.2 3.4 2.7 3.9 6.3
r (%) 1.9 2.1 4.5 1.9 5.0 1.8 9.0 4.7 4.0 5.6
RSME (%) 4.5 4.0 5.0 3.8 5.3 3.5 9.5 5.3 5.4 8.2
Piperacillin
x̄ (mg/l) 1.47 1.51 98.77 101.69 189.03 197.66 302.36 298.77 0.51 0.50
CV (%) 5.5 4.0 2.9 3.4 4.3 2.5 2.7 3.5 2.3 7.3
r (%) 1.9 0.4 1.2 1.7 5.5 1.2 8.1 0.4 2.0 0.0
RSME (%) 5.4 3.7 3.0 3.6 5.9 2.6 2.7 3.2 3.0 6.6
Observed mean concentration, x̄; coefficient of variation, CV; relative bias, r; relative root-mean-square-error, RSME; quality control samples, QC.
Table  4
Dilution integrity experiments spiking hemolytic, icteric and lipemic samples (n = 5) with antibiotic concentrations of 75% ULOQ and twice the ULOQ.
Analyte
Dilution factor
1:2 1:3 1:5
 (mg/l) x̄  (mg/l) CV (%) r (%)  (mg/l) x̄ (mg/l) CV (%) r (%)  (mg/l) x̄ (mg/l) CV (%) r (%)
High concentration (75% ULOQ)
Cefepime 62.5 65.3 4.1 4.4 41.7 43.6 3.0 4.7 25.0 25.1 3.6 0.4
Meropeneme 40.0 43.8 4.0 9.4 26.7 30.3 3.4 13.7 16.0 18.2 3.2 13.6
Ciprofloxacin 3.3 3.3 9.1 2.2 2.2 2.2 4.2 1.9 1.3 1.4 3.7 5.1
Moxifloxacin 3.8 3.8 8.0 0.6 2.5 2.6 2.7 3.0 1.5 1.5 5.1 0.8
Linezolid 13.8 13.8 2.9 0.2 9.2 9.4 3.6 2.9 5.5 5.8 3.4 4.8
Piperacillin 112.5 118.3 4.3 5.2 75.0 81.0 3.6 8.0 45.0 47.8 3.1 6.1
Concentration out of range (2x ULOQ)
Cefepime 200.0 196.6 7.9 1.7 133.3 128.1 2.8 4.0 80.0 84.7 6.8 5.8
Meropeneme 120.0 126.8 4.1 5.6 80.0 83.1 2.6 3.9 48.0 50.8 1.9 5.9
Ciprofloxacin 10.0 9.8 7.5 2.4 6.7 6.2 1.9 7.3 4.0 4.1 5.0 1.6
Moxifloxacin 10.0 10.0 1.7 0.1 6.7 7.0 2.4 5.0 4.0 4.1 3.5 1.4
Linezolid 50.0 49.3 7.8 1.4 33.3 31.3 3.2 6.0 20.0 20.8 8.4 3.9
30
E variat
U
f
T
e
a
r
Piperacillin 400.0 442.5 5.8 10.6 266.7 
xpected nominal concentration, ; observed mean concentration,x̄; coefficient of 
For the three concentration tested (3x LLOQ, 20% ULOQ, 75%
LOQ) using 6 samples the recovery rates for all analytes were
ound to be 77.9–110.3% with deviations of the mean value ≤13.4%.
he internal standard (IS) constantly compensated for matrix
ffects, given by the IS normalized matrix factors in between 94.6
nd 105.4% with a CV ≤8.3%. Imprecision of analyte peak area
esponses never exceeded 9.9% for all concentrations tested.3.4 0.9 13.8 160.0 181.2 1.2 13.2
ion, CV; relative bias, r.
3.1.8. Stability experiments
All  antibiotic concentrations tested were stable with an absolute
deviation (%D) from the nominal concentration of fresh coun-
terparts that was  consistently lower than 13.0%. Stability was
therefore given for serum samples stored 6 h at RT, 24 h at 4 ◦C,
two weeks at −20 ◦C and up to three repeated freeze-thaw cycles
(–80 ◦C and RT). Processed specimen at autosampler temperature
(10 ◦C, ±5 ◦C) was  also stable for 24 h (absolute%D value ≤ 11.1%).
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. Discussion
In the present study we developed and validated a HPLC–MS/MS
ulti-analyte method for simultaneous quantification of cefepime,
eropenem, ciprofloxacin, moxifloxacin, linezolid and piperacillin
sing corresponding isotope-labelled internal standards. Com-
ercially available human serum was used as matrix for the
reparation of calibrators and quality control samples, guarantee-
ng absence of interfering drugs. Of all protein precipitating agents
ested, best extraction yields and reproducibility were obtained
ith a methanol-methyl-tert-butyl ether (90:10, v/v) mixture. Ana-
yte extraction was performed within 25 min, followed by a 4 min
tep-elution HPLC chromatographic separation using a C8 reverse
hase column. The major advantages of the method in this study
re the simple sample preparation and instrumentation setting,
hich should allow antibiotic TDM in laboratories with limited
ass spectrometry capabilities.
Although mere protein precipitation is not the best procedure
o prevent matrix effects, our sample preparation protocol pro-
ided acceptable internal standard normalized matrix factor results
ith a CV ≤8.3%. For the analytes in this study, imprecision and
naccuracy (both intra- and interassay) were ≤12.5% for all quality
ontrol samples and the lowest calibrator (LLOQ), complying with
he EMA  requirements. Extensive testing with TDM quality controls
rom our routine laboratory and patient samples (non-ICU and ICU)
ave no significant signals at analytic retention times and therefore
onfirmed assay selectivity. The method was also not disturbed by
evere hemolysis, icterus and lipemia.
Our short-term stability experiments gave different results
hen compared with previously published work [44]. Given that
recautions should be taken to prevent beta-lactam degradation
n vitro, we recommend immediate extraction after blood collec-
ion or temporary storage up to one week at −20 ◦C if immediate
rocessing is not possible.
Various  multi-analyte LC–MS/MS methods have been published
n the recent years [28,33–37,47,48], however many of these
pproaches quantify structurally related antibiotics from the beta-
actam class only (extensively reviewed in [38]). In contrast to other
tudies, our TDM panel allows quantification of substances with dif-
erent physico-chemical properties, including ß-lactam antibiotics,
s well as the oxazolidinone linezolid and fluorchinolone drugs.
he rationale for quantifying cefepime, meropenem, ciprofloxacin,
oxifloxacin, linezolid and piperacillin in a single multi-analyte
ssay is that these antibiotics are most frequently used in ICUs
nd are of uttermost importance for routine TDM in critical illness
49,50]. A TDM panel including relevant antibiotics from different
lasses can therefore be more efficient in terms of high sample
hroughput, minimal turn-around time and costs when compared
o mono-analyte and class-specific quantification methods that
equire multiple instruments and different chromatographic sol-
ents.
For the implementation of local and national antibiotic steward-
hip programs, routine TDM is becoming increasingly important
n the clinical setting [19]. Still, common concentrations required
or maximal antimicrobial efficacy and dose adjustement strategies
re controversially discussed [10,18,20,51]. Uniform therapeutic
anges are not defined for a specific antibiotic substance; the central
omponent of the PK/PD target is the minimal inhibitory con-
entrations (MIC) of the causative pathogen. For time-dependant
ntibiotics, such as ß-lactams, the efficacy is related to the time
f the free (or unbound) concentration above the MIC  (f T>MIC ). In
his context maximal bactericidal activity is reported for through
oncentrations that exceed the MIC  four to five times (f T>4-5xMIC )
16,52]. When quantifying total ß-lactam concentrations, includ-
ng both the free and bound antibiotic fraction, the target range
as to be increased. This is in particular relevant for piperacillin,iomedical Analysis 152 (2018) 102–110
with  the high average protein binding fraction of approximately
30% [53]. According the European Committee on Antimicrobial
Susceptibility Testing (EUCAST) the threshold for the treatment
of wild-type Pseudomonas spp is therefore 64 mg/l for unbound
piperacillin, which corresponds to 91.4 mg/l total piperacillin [40].
For the oxazolidinone linezolid maintenance of the through level
above the MIC  (f T>MIC ), preferably ≥2 mg/l, is considered the most
relevant marker for efficacy [22]. Contrary, fluorchinolones do act
as concentration-dependant antimicrobials with a certain degree
of time dependence, whose efficacy is mainly related to the ratio
of the area under the concentration time curve (AUC) and the MIC
(AUC0-24/MIC). As quantification of the AUC requires multiple blood
sampling, quantification of the peak concentration Cmax is gener-
ally preferred. In this context, the target ratio of a Cmax/MIC of ≥ 10
can be used as universal therapeutic threshold for fluorchinolones
[54,55].
In contrast to other approaches our TDM assay has a broad cal-
ibration range. It allows quantification of concentrations close to
the MIC  of susceptible pathogens and also pharmacokinetic peak
levels that may  be obtained after bolus administration in standard
dosage regimen. Consequently, our procedure allows quantifica-
tion of through, as well as peak levels and also calculation of the
AUC, using a uniform extraction protocol without the necessity of
specimen dilution. Should the antibiotic concentration of a sample
still exceed the ULOQ of our assay it may  be diluted with distilled
water (up to 1:5) prior to processing.
Carry-over was negligible for all antibiotics, except for
ciprofloxacin at the LLOQ of 0.05 mg/l. Analytic carry-over was
unavoidable, presumably due to inherent properties of our
autosampler system. When using ciprofloxacin as antimicrobial the
lowest target peak concentration needed for treatment is 0.3 mg/l
for Neisseria spp (MIC of 0.03 mg/l) according to EUCAST breakpoint
tables [40]. As the carry-over of 0.21% would increase this threshold
merely by 5% when following a sample with a high peak concen-
tration of 7.5 mg/l, it can be considered clinically non-relevant.
In conclusion, we report a simple and fast method for simul-
taneous quantification of cefepime, meropenem, ciprofloxacin,
moxifloxacin, linezolid and piperacillin in serum that covers the
clinical useful concentration ranges. Being robust with regard
to analytic selectivity, linearity, matrix effects, and stability the
described method allows routine antibiotic TDM in clinical labo-
ratories with limited HPLC–MS/MS capacity.
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Abstract
There is an ever-increasing demand for the therapeutic drug monitoring of antibiotics in many clinical facilities, particularly with regard to the
implementation of hospital antibiotic stewardship programs.
In the current work, we present a multiplex high-performance liquid chromatography-tandem mass spectrometry (HPCL-MS/MS) protocol for the
quantification of cefepime, meropenem, ciprofloxacin, moxifloxacin, linezolid, and piperacillin, commonly used antibiotics in intensive care units.
The method was previously comprehensively validated according to the guideline of the European Medicines Agency.
After a rapid sample cleanup, the analytes are separated on a C8 reverse-phase HPLC column within 4 minutes and quantified with the
corresponding stable isotope-labeled internal standards in electrospray ionization (ESI+) mass spectrometry in multiple reaction time monitoring
(MRM). The presented method uses a simple instrumentation setting with uniform chromatographic conditions, allowing for the daily and robust
antibiotic therapeutic drug monitoring in clinical laboratories. The calibration curve spans the pharmacokinetic concentration range, thereby
including antibiotic amounts close to the minimal inhibitory concentration (MIC) of susceptible bacteria and peak concentrations (Cmax) that are
obtained with bolus administration regimens. Without the necessity of the serum dilution before the sample cleanup, the area under the curve for
an administered antibiotic can be obtained through multiple measurements.
Video Link
The video component of this article can be found at https://www.jove.com/video/58148/
Introduction
Although antibiotics have revolutionized the practice of medicine, severe bacterial infections remain a leading cause of morbidity and mortality in
critical illnesses1. In this regard, the prompt administration of a suitable anti-infective in an adequate dosage is of the uppermost importance for
disease control2.
A growing body of evidence demonstrates that the empirical treatment with broad-spectrum antibiotics is becoming increasingly problematic
with the complexity of patient populations. This is especially true for intensive care units (ICU), where a tremendous inter-individual variability of
key pharmacokinetic (PK) parameters is frequently observed3,4. Accordingly, ICU patients are at imminent risk of sub-therapeutic levels with the
danger of an insufficient therapeutic success5,6. Then again, patients are unnecessarily exposed to excessively high antibiotic concentrations
that may result in serious adverse events with no clinical benefits7. Both the antibiotic misuse and the insufficient dosing have also fueled the
dissemination of antibiotic resistance, which is becoming an ever-growing threat to public health8.
To improve the use of antibiotics and to preserve their effectivenessas long as possible, the World Health Organization has launched a global
action plan on antimicrobial resistance in 20159. Antibiotic stewardship programs constitute an essential cornerstone of prudent antimicrobial use
in national public health strategies10, helping clinicians to improve the quality of patient care11 and, at the same time, significantly reducing the
antibiotic resistance12. Antimicrobial dosing in individual patients through the application of therapeutic drug monitoring (TDM) is a key instrument
in this context13.
To date, commercially available TDM assays are only available for the glycopeptide antibiotics and aminoglycosides. The quantification of
substances from other classes commonly requires an in-house method development or validation that can be cumbersome. We, therefore,
present in detail the protocol for a robust mass spectrometry-based assay that can be used for the quantification of the most relevant antibiotics
in ICU within their clinical relevant concentration ranges14. The method was recently established in our mass spectrometry facility and has been
applied for the routine TDM in ICU since then. The procedure uses a straightforward and simple analytical setting with a uniform sample cleanup,
allowing for the rapid implementation of antibiotic TDM in many facilities with mass spectrometry capabilities.
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The protocol described here was optimized for the quantification of cefepime, meropenem, ciprofloxacin, moxifloxacin, linezolid, and piperacillin
in human serum, using isotope dilution liquid chromatography (LC) in combination with a tandem mass spectrometry (MS/MS). For the isotope
dilution LC-MS/MS methodology, stable isotope-labeled compounds are added to a sample of interest with a specific matrix (e.g., serum).
Isotope-labeled standards can be distinguished from their unlabeled counterpart, namely the analyte of interest, due to different molecular
weights of the natural molecule and their fragmentation products, termed a parent-ion-to-daughter-ion transition. As isotope-labeled compounds
have an almost identical overall physicochemical behavior compared to their unlabeled counterpart, they are ideal internal standards for the
MS/MS, allowing a nearly matrix-independent analyte quantification with a high degree of accuracy15. Nowadays, many stable isotope-labeled
internal standards that can be used for small-molecule quantification, including the TDM of antimicrobials, are commercially available.
The chromatographic separation of the antibiotic analytes in the described protocol is performed with an analytical C8 alkyl-chain-length reverse-
phase column (100 mm x 2.1 mm, 3 µm particle-size). During the method development, the internal standard normalized matrix factors for all
analytes was between 94.6% and 105.4%, with a coefficient of variation of ≤8.3%14.
Protocol
NOTE: It is recommended to work in a fume hood when handling organic solvent, such as methanol. Prepare all buffers and mobile phases in
volumetric flasks. If not otherwise specified, the solutions can be stored at room temperature for up to 1 month after preparation.
1. Preparation of the Calibrators and Quality Control Samples
NOTE: A corresponding data analysis sheet for the preparation of stock and spike solutions is given in the Supplemental File. For reasons of
traceability, insert the manufacturer, catalog number, and a lot number of each antibiotic in the corresponding columns. Dissolve all antibiotics in
a cold storage at 4 °C and keep the working time as short as possible.
1. Prepare 100 mL of 25% methanol in water: prefill a 100 mL volumetric flask with 25 mL of absolute methanol and fill it up to 100 mL with
distilled water.
2. Prepare 10 mL of 200 mM acetic acid in water: prefill a 10 mL volumetric flask with 9 mL of HPLC grade water, add 115 µL of glacial acetic
acid (99.5% purity, 17.4 M), and add distilled water up to 10 mL.
3. Prepare 25 mL of 25% methanol in water with 20 mM acetic acid: prefill a 25 mL volumetric flask with 2.5 mL of the aqueous 200 mM acetic
acid solution, add 6.25 mL of absolute methanol, and fill up the flask to 25 mL with distilled water.
4. Use a precision scale to weigh the proper amounts of antibiotics in 15-mL conical tubes as described in the Supplemental File in the column
initial weight.
5. Prepare stock solutions of the fluoroquinolones, ciprofloxacin, and moxifloxacin in the 25% methanol-water including 20 mM acetic acid. To
do this, add the corresponding volume to the weighted quantities as described in the Supplemental File in the column "final volume". Rapidly
dissolve the fluoroquinolone antibiotics in an ultrasound bath for 2 min and by intense vortexing.
6. Prepare stock solutions of cefepime, meropenem, linezolid, and piperacillin in the 25% methanol-water. To do this, add the corresponding
volume to the weighted quantities as described in the Supplemental File in the column final volume and rapidly dissolve the antibiotics by
intense vortexing. Dissolve meropenem as the last substance.
7. Combine the stock solutions of all the antibiotics as described in the corresponding volume of stock solution chart in the Supplemental File
to yield tenfold concentrated spike-solutions.
8. Spike nine volumes of drug-free serum with one volume of the tenfold concentrated spike solutions to obtain the serum calibrators 0–7 and
quality controls (QC) A–D. For example, add 0.5 mL of spike solution to 4.5 mL of serum in a 10-mL polypropylene tube and incubate it for 15
min in the cold storage at 4 °C on a roller mixer at 50 rpm.
9. Use a repetitive pipette to generate 100 µL aliquots of the calibrators and QCs in 1.5 mL polypropylene tubes.
10. Store the calibrators, quality controls, and antibiotic stock solutions at -80 °C for up to six months.
11. For each antibiotic, also prepare a neat solution containing 1,000 mg/L of a single antibiotic. Dilute the corresponding stock solution with an
appropriate diluent (e.g., for ciprofloxacin, use 25% methanol-water including 20 mM acetic acid).
 
NOTE: The neat antibiotic solutions are required for the instrument-tuning only.
2. Preparation of the Internal Standards Mix
NOTE: Internal standards are isotope-labeled counterparts of the analytes of interest that are added to a sample during sample cleanup. As
the internal standards have almost identical overall physicochemical properties to their unlabeled counterparts, they compensate for the matrix
effects of a given sample.
1. Prepare 10 mL of 50% methanol in water by adding 5 mL of absolute methanol to a 10 mL shake flask and fill it up to 10 mL with distilled
water.
2. Prepare 10 mL of 50% methanol in water including 20 mM acetic acid. To do this, add 1 mL of 200 mM acetic acid to a 10 mL flask, add 5 mL
of absolute methanol, and fill it up to 10 mL with distilled water.
3. Generate stock solutions of internal standards (IS) with 1,000 mg/L directly in the vials provided by the manufacturer. Dissolve
cefepime-13C1
2D3 sulfate in distilled water, meropenem-D6, linezolid-D3, and piperacillin-D5 in a 50% methanol-water solution. Dissolve
ciprofloxacin-D8 in 50% methanol-water with 20 mM acetate and moxifloxacin hydrochloride-
13C1D3 in distilled water with 20 mM acetate.
4. Combine the IS stock solutions in a 1.5 mL polypropylene tube to yield a fivefold concentrated internal standard mix. Add 10 µL of
cefepime-13C1
2D3, 10 µL of meropenem-D6, 1 µL of ciprofloxacin-D8, 2 µL of moxifloxacin hydrochloride-
13C1D3, 2 µL of linezolid-D3, and 10
µL of piperacillin-D5 to 965 µL of 25% methanol-water.
5. Store the internal standard stock solutions and the fivefold concentrated IS mix at -80 °C.
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3. Patient Sample Storage
NOTE: Ensure that the serum is obtained as fast as possible and that the cold chain of frozen samples is maintained.
1. Collect the whole blood in the serum collection tubes.
2. Let the blood clot for 20–30 min at room temperature.
3. Separate the serum from the blood by centrifugation at 2,000 x g for 10 min.
4. Transfer the supernatant to a clean polypropylene tube.
5. Store the serum up to six months at -80 °C until it is assayed. Alternatively, store the samples up to 3 days at -20 °C.
4. Buffer Preparation for Chromatography
1. To prepare 1 M ammonium formate in water, dissolve 6.306 g of ammonium formate in 100 mL of HPLC grade water using a 100 mL shake
flask. Store the solution up to 1 month at 4 °C.
2. Prepare the mobile phase A [10 mM ammonium formate in water-formic acid (99.9:0.1 v/v)]. Prefill a 1,000 mL volumetric flask with
approximately 500 mL of HPLC grade water, add 1 mL of formic acid and 10 mL of the 1 M ammonium formate solution, and fill it to 1,000
mL with HPLC grade water. Transfer mobile phase A to a clean glass bottle and connect it to the HPLC system. Store mobile phase A up to 2
weeks at room temperature.
3. Prepare the mobile phase B. Transfer HPLC-grade absolute methanol into a clean glass bottle and connect it to the HPLC system.
4. Use absolute methanol as the needle wash solvent and connect the corresponding tube to the glass bottle containing mobile phase B.
5. Generate the seal and a purge solvent of methanol-water-formic acid (7:92.9:0.1, v/v/v). Prefill a 1,000 mL volumetric flask with approximately
500 mL of distilled water, add 70 mL of absolute methanol, 1 mL of formic acid, and add distilled water to 1,000 mL. Transfer the solvent to a
clean glass bottle and connect it with the HPLC system.
 
Note: Various autosampler systems use both a strong and a weak needle wash solvent. In such a case, prepare the wash solutions according
to the manufacturer’s recommendations. For example, do the strong wash with methanol-water-isopropylic alcohol (70:20:10, v/v/v) and the
weak wash with water-methanol (95:5, v/v).
5. Instrument Tuning
NOTE: This step is performed for the set-up of the method on a specific mass spectrometer.
1. Dilute the neat 1,000 mg/L analyte and the internal standard solutions 1:10 or 1:100 in a mixture of mobile phase A and B (50:50, v/v),
depending on the detector signal intensities. Tune the mass spectrometer with the autotune function or do a manual tuning for the following
parent-to-daughter ions transitions14: cefepime (481.0 > 167.0/395.7), cefepime-13C1
2D3 (485.1 > 167.1/400.0), meropenem (384.1 >
114.0/141.0), meropenem-D6 (390.1 > 114.0/147.2), ciprofloxacin (332.0 > 231.0/245.0), ciprofloxacin-D8 (340.1 > 235.1/249.3), moxifloxacin
(402.0 > 261.0/383.9), moxifloxacin-13C1D3 (406.1 > 265.1/388.0), linezolid (338.0 > 235.0/296.0), linezolid-D3 (341.1 > 235.1/297.1),
piperacillin (518.0 > 143.0/358.9), and piperacillin-D5 (523.1 > 142.8/364.1).
2. For instruments with autotuning, use the autotune function to automatically adjust the voltage and settings of the MS inlet through the
detectors.
3. For instruments with manual tuning, adjust the settings (e.g., collision voltage and collision energy) until the optimum (usually the maximum)
signal intensity is obtained at the detector for each parent and daughter ion. For example, plug a mixing tee, deliver mobile phase A and B
(50:50, v/v) at 0.5 mL/min, and continuously infuse the neat antibiotic or internal standard with a flow rate of 0.1 mL/min.
6. HPLC-MS/MS Set-up
NOTE: Features of the mass spectrometer, HPLC system (including the autosampler), and the corresponding software depend on the
manufacturer. Adapt the mass spectrometer parameters and the wash procedure according to the manufacturer’s recommendations.
1. Store the mass spectrometer parameters in a corresponding 'MS tune file'. Use electrospray ionization in the positive mode (ESI+) for
all analytes. Adapt the ion source settings for the instrument used (e.g., a capillary voltage of 1.5 kV, a source temperature of 120 °C, a
desolvation temperature of 400 °C, a desolvation gas flow rate of 600 L/h, an RF lens voltage of 0.1 V, and a dwell time of 80 ms).
2. Specify the analyte and internal standards tune parameters (e.g., capillary voltage, collision energy) in an 'MS file'.
3. Set the autosampler conditions as follows in the 'inlet file': the sample temperature at 10 °C with a limit of ± 5 °C; the wash sequence at 1x
purge-wash-purge with a 600 µL purge volume replacement.
4. In the above-mentioned 'inlet file', set the flow rate to 0.4 or 0.5 mL/min, the run time to 4 min, the pressure high limit to 345 bar, and
the column temperature to 30 °C with a limit of ± 5 °C. Add the solvent name of mobile phases A and B and set them to 7% B/93% A,
respectively.
5. Program the chromatographic gradient in the 'inlet file' as follows: 0.00–0.10 min with 7% mobile phase B/93% A, 0.11–0.60 min with 65%
mobile phase B/35% A, 0.61–2.10 min with 95% mobile phase B/5% A, 2.11–4.00 min with 7% mobile phase B/93% A.
 
NOTE: Calculate the extra-column volume, the hold-up volume for the instrumental platform, and the analyte retention factors as described in
the USP <621> Chromatography guideline16.
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7. Sample Measurement Master File
NOTE: With the 'sample measurement master file', the patient samples are specified, the HPLC-MS/MS analysis is started, and the data
evaluation is performed. Two separate template files including a low- and high-quality control pair are generated; one template includes QC pair
A and C, the other one QC pair B and D.
1. Create a new 'sample measurement master file'. Select the above-mentioned 'MS tune file', 'MS file', and 'inlet file' (section 6), insert them in
each sample line, and specify the injection volume with 15 µL.
2. In ascending order, add the “sample text” for calibrators 0–7 and quality control (QC) pair A/C or QC pair B/D.
3. Specify the sample type. Select the sample type “standard” for the calibrators and “QC” for the quality control pairs.
4. Specify the concentration of each antibiotic substance for the corresponding calibrators and quality controls (see the spreadsheet,
concentration [µg/mL] Cal 7–Cal 0, QC A/C or B/D,).
5. Program the 'data evaluation method'. Use the transitions that were optimized during the instrument tuning (section 5). Match each antibiotic
with the corresponding isotope-labeled standard (e.g., meropenem - meropenem-D6).
8. Sample Cleanup and HPLC-MS/MS Analysis
NOTE: For each sample batch, a paired quality control set with a low and high antibiotic concentration (QC A/C or QC B/D) is processed and
analyzed. Between different batches, the paired QC samples are used in an alternate sequence (e.g., on day 1, select the 'sample measurement
master file' including QC pair A/C; on day 2, select the one including QC pair B/D. The processing of the serum samples is illustrated in Figure 1.
1. Prepare the precipitation agent 10% methyl-tert-butyl ether in methanol (10:90, v/v) (e.g., prefill a 25-mL volumetric flask with 2.5 mL of
methyl-tert-butyl ether and fill it to 25 mL with absolute methanol).
2. Place the C8 reverse phase into the column chamber. Connect it to the HPLC and mass spectrometer in the direction of the flow.
3. Generate the sample list. Open the corresponding 'sample measurement master file' template and add the patient samples meant to be
processed to the list. Generate groups of up to 20 patient samples and flank them with the corresponding quality control pair.
4. Wet-prime the HPCL system using the 'inlet file' control software: set the “wet prime” function to 50% mobile phase A/50% B, and wet-prime
for 2 min with a flow rate of 1 mL/min.
5. Refresh the syringe. To do this, execute 6 strokes of 600 µL in the control software.
6. Equilibrate the C8 reverse phase column. Using the software, turn on the flow in the 'inlet file' and flush it with 7% mobile phase B/93% A for
a minimum of 5 min, using a flow rate of 0.5 mL/min. Verify the column temperature of 30 °C.
7. Thaw the patient samples, one aliquot of calibrators 0–7, and a quality control pair (either A/B or C/D).
8. With a repetitive pipette, add 25 µL of the internal standard mix to the 100 µL calibrator, QC sample, or patient serum in a 1.5 mL
polypropylene tube, and vortex the tube for a few seconds.
9. Incubate the mixture for 5 min at room temperature on a benchtop shaker (e.g., at 1,200 rpm).
10. With a repetitive pipette, add 150 µL of a precipitation reagent to the sample-internal standard mix.
11. Again, vortex the tube for a few seconds and incubate it for 5 min at room temperature on a benchtop shaker (e.g., at 1,200 rpm).
12. Centrifuge the suspension at 20,000 x g in a tabletop centrifuge for 10 min at 4 °C.
13. Dilute the supernatant 1:3 with HPLC grade water using a glass vial with a micro-insert and load it as processed samples to the autosampler.
14. Manually start the HPLC-MS/MS analysis in the 'sample measurement control file'.
 
NOTE: For prolonged storage, thoroughly flush the analytical column according to the manufacturer’s recommendation [e.g., 0.5 mL/min
methanol-water (50:50, v/v)] to prevent phase collapse.
 
Figure 1: Schematic representation of the sample cleanup. Protein precipitation at the high centrifugal force gives a dense pellet and
clear supernatant, indicating that protein precipitation was complete. The entire processing time is approximately 30 min, including the sample
cleanup, the chromatographic separation, and the MS/MS analysis. Please click here to view a larger version of this figure.
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9. Quality Assessment and Quantification
1. To process the samples, open the corresponding 'sample measurement control file', select the calibrators, quality controls, and patient
samples, and evaluate them with the 'antibiotics quantification method'.
2. Check whether the peaks for a specific analyte are properly integrated. Inspect the peaks for each calibrator, QC, and patient sample, and
manually reintegrate them at the baseline if necessary.
3. Study the calibration curve and examine whether it fulfills the following quality criteria: a) linearity over the entire calibration range, b) a
calibration coefficient r2 > 0.995, c) the deviation of each calibration standard within ± 15% of the nominal value, except for the lower limit of
quantification (LLOQ), where ± 20% is required.
4. Reject a calibration standard not complying with the above-mentioned criteria and re-evaluate the calibration curve, including the regression
analysis.
5. Study the quality controls and examine whether the deviations are within ± 15% of the nominal value.
6. If the concentration of a patient sample exceeds the concentration of the highest calibrator, dilute the sample with distilled water, up to 1:5
(e.g., 100 µL of serum plus 400 µL of distilled water) before the sample cleanup. Reperform steps 8.8–8.14 for that specific sample and
reprocess it.
Representative Results
Using the described protocol, a typical chromatogram is depicted in Figure 2. According to the United States Pharmacopeia (USP)
chromatography guidelines16, the column dead volume in the present system was determined with ~0.22 mL and the extra-column volume
(including the injector, tubing, and connectors) with ~0.08 mL, giving a hold-up volume of ~0.30 mL. The calculated retention factors for all
analytes were 2.8 (for cefepime) - 4.2 (for piperacillin).
 
Figure 2: Typical analytical chromatogram with normalized signal intensities. The antibiotics are eluting in the following order: cefepime
(green), meropenem (brown), ciprofloxacin (red), moxifloxacin (black), linezolid (orange), and piperacillin (purple). The retention times, which
are given in minutes, and the analyte peak symmetries vary, depending on the exact composition of the mobile phases, the flow-rate, the
chromatography tubing, and the analytical column age. Please click here to view a larger version of this figure.
Figure 3A contains a sample chart list for the processed samples, including the calibrators 0 - 7 ("Kalibrator 0" - "Kalibrator 7"), quality controls,
and patient sera, that are indicated with the injection number (#); the sample identification text (Sample Text); the measured concentration in mg/
L (Conc.); the sample type that is either a blank, standard, quality control, or patient sample (Type); the nominal concentration of the calibrators
in mg/L (Std. Conc); the analytical retention time (RT); the response that is the ratio of the peak area of the analyte/peak area IS (Response);
the deviation from the nominal concentration value (%Dev); the vial position (Vial); and the acquisition time (Acq.Time). The key parameter used
for the quantification is the Response, gradually increasing with the analyte concentration, due to the constant amount of added isotope-labeled
internal standard.
Figure 3B shows the calibration curve. In regression, the coefficient of determination r2 should be > 0.995. The following calibration model is
used for all analytes described in this method: curve type = linear; origin = included; weighting = 1/x; axis transformation = none. In the given
example, the calibration curve and quality controls fulfill all quality criteria: r2 > 0.995 for the calibration curve and the deviation of the calibrators
(including the LLOQ) and the QC samples is within ± 15% of the nominal value.
The measured parent-to-daughter ion transitions (MRM) are given in Figure 3C, showing four peaks at the same retention time: the two upper
peaks depict two transitions that are measured for the analyte of interest, the lower two peaks represent the transitions for the corresponding
isotope-labeled internal standard. For the quality assessment, the analyte peaks in the respective retention time windows are visually checked
and manually reintegrated at the baseline, when necessary.
The minimally inhibitory concentration (MIC) is the central component of the antimicrobial TDM, defining the pharmacokinetic exposure that is
required to achieve a target pharmacokinetic/pharmacodynamic (PK/KD) ratio13,17. Accordingly, the target antibiotic TDM concentration levels
are expressed in relation to the MIC of the causative pathogen. Given that the action of beta-lactam antibiotics is time-dependent, their efficacy is
maximized through the achievement of the therapeutic concentrations that exceed the MIC 4x -5x (fT > 4-5x MIC).When facing unknown infectious
pathogens, the target trough concentration range of free (protein-unbound) piperacillin is, therefore, 64 mg/L, corresponding to approximately 90
mg/L total piperacillin18.
The first patient (sample #11) has a satisfactory high serum trough level of 83.4 mg/L piperacillin that is also sufficient for problem pathogens,
such as Pseudomonas aeruginosa. The second patient (sample #12) has a concentration of approximately 0.2 mg/L, which is below the
lowest calibrator (LLOQ). Perhaps the patient has recovered, and the administration of piperacillin was discontinued. The result "< 0.5 mg/L"
is, therefore, reported in the hospital information system. The third patient (sample #13) has a low piperacillin trough concentration of only 5.3
mg/L that is not sufficient for the clear majority of pathogens. For effective antimicrobial chemotherapy, the dosage should be increased by the
physician.
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Figure 3: Exemplary quality assessment and quantification for the analyte piperacillin. These panels represent the mass spectrometry
data analysis. (A) This panel shows the sample list, including the calibrators (Standard, samples #1 - #8), quality controls (QC, samples #9
and #10), and patient sera (samples #11 - #13). Calibrator 0 refers to the blank without analyte, but with the addition of an internal standard.
9951 represents QC B, 9953 represents QC D. (B) This panel shows the calibration curve for piperacillin. The percentage deviations from the
nominal calibrator concentrations are given in the upper graph (y-axis: residual), the lower graph depicts the linear calibration range. (C) This
panel shows the multiple reaction time monitoring (MRM) for piperacillin and the corresponding internal standard piperacillin-D5 for patient serum
sample #12. Two parent-to-daughter ion transitions are presented with their retention time and respective signal intensities. Please click here to
view a larger version of this figure.
Supplemental File. Please click here to download this file.
Discussion
In this manuscript, we report the protocol for a simple and robust tandem mass spectrometry-based method for the quantification of frequently
used antibiotics in ICU19, namely cefepime, meropenem, ciprofloxacin, moxifloxacin, linezolid, and piperacillin14. A spreadsheet accompanies
the manuscript for the preparation of antibiotic stock solutions, calibrators, and quality controls, taking into account the purity of the antibiotics
and the molecular weight of their counterions. Given that the concentrations of the antibiotics are rather high, their quantification should be no
particular challenge from an analytical perspective. Accordingly, we are confident that this protocol is applicable to various MS instrumental
platforms. For a method transfer, users are encouraged to quantify the extra-column volume and hold-up volume of their chromatographic
system and to adapt the gradient start time accordingly16. During the method set-up, the system should also be evaluated for carry-over and, if
necessary, a blank sample must be injected after the highest calibrator and patient samples with high antibiotic concentrations. Users must also
consider the possibility of detector saturation that occurs when too many ions enter a tandem mass spectrometer. Relevant detector saturation
can be eliminated with smaller injection volumes, a higher analyte dilution during the sample cleanup, and/or a detuning of a target analyte (e.g.,
downgrading the optimal voltage settings).
Contrary to other methods, the calibration range allows both a quantification of concentrations close to the MIC of susceptible pathogens, as well
as peak concentrations (cmax) that are obtained with a bolus administration. The highest Cmax-values for adults are reported in the corresponding
professional information sheets on the FDA drug safety database as follows: 163.9 mg/L for cefepime20, 112 mg/L for meropenem21, 4.6 mg/L
for ciprofloxacin22, 4.1 mg/L for moxifloxacin23, 21.2 mg/L for linezolid24, and 298 mg/L for piperacillin25. Antibiotic concentration monitoring in the
patient's blood circulation allows a dose adjustment to the susceptibility of the involved pathogens, but the pharmacokinetic area under the curve
can also be obtained through multiple blood sampling with the given protocol.
Many antibiotics (especially beta-lactam meropenem) are chemically unstable once dissolved. The most critical step in this protocol is, therefore,
the preparation of the stock solutions, calibrators, and quality controls under cold conditions26,27. In that respect, it is also essential to freeze
patient samples as quickly as possible. Although serum storage at -80 °C is recommended26, our stability experiments show that samples can
also be stored up to 3 days at -20 °C without any significant decrease of antibiotics concentrations (even at the trough levels).
We recommend performing a system suitability test before each HPLC-MS/MS analysis of patient samples (e.g., with calibrator 3). Generally,
a system suitability test is used to verify the repeatability of the LC-MS/MS system and to see if it is also adequate for the analysis to be done.
Thus, for instance, decreasing signal intensities are caused by a contamination of the MS sweep cone, which, then, requires its cleaning with
an organic solvent. To keep the MS source clean, a divert valve can be introduced after the chromatography column, directing "analyte-free"
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portions of the mobile phase to the waste before they reach the mass spectrometer. On the other hand, an overall increase of the pressure can
indicate column clogging over time. To increase the column longevity usage of a cost-effective precolumn filter is recommendable. If the pressure
still continues to be a problem, a flow rate of 0.4 mL/min can also be used with the chromatographic gradient in this protocol.
A minor limitation of this technique is that it requires three separate manual steps for sample clean-up, resulting in a total turnaround time of
approximately 30 min. Adding the isotope-labeled internal standards to the precipitation agent may save some processing time. However, this
should only be done for high sample throughput rates and with the precipitation agent being stored in the cold (e.g., at -20 °C), as the internal
standards also degrade in vitro at elevated temperatures.
The described protocol has been developed for sample processing in standard 1.5 mL polypropylene tubes. Should a higher throughput rate be
required for antibiotic TDM, the procedure can be upgraded to the multi-well plate format using adequate centrifuge inserts or filter plates with a
vacuum manifold.
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Introduction:  The  aim  of this  project  was  to develop  and  validate  an  isotope-dilution  liquid  chromatogra-
phy  high  resolution  mass  spectrometry  (LC-HRMS)  method  for the  quantification  of  the 11  most  widely
used  systemic  antimycotics  and  to study  whether  HRMS  is a feasible  alternative  for  therapeutic  drug
monitoring  (TDM)  when  compared  to tandem  MS (MS/MS)  technology.
Methods: After  protein  precipitation,  followed  by automated  online  sample  clean-up  the  analytes  were
separated  within  4 min  on  a C18  column  using  an  acetonitrile-water  gradient.  Eleven antimycotics,
namely  5-flucytosine,  amphotericin  B, anidulafungin,  fluconazole,  isavuconazole,  itraconazole,  ketocona-
zole,  micafungin,  OH-itraconazole,  posaconazole  and  voriconazole  were  finally  quantified  in  full MS scan
mode  using  positive  electrospray  ionization  (ESI  +)  with  a mass  range  fromm/z  110–1300  using HRMS.  The
method  was  comprehensively  validated  on  the  basis  of  the  European  Medicines  Agengy  (EMA)  method
validation  protocol  using  commercially  available  IVD  kit  components.
Results: Good  linear  relationship  between  peak  area  responses  and  drug  concentrations  (R2 >  0.995)  and
excellent  selectivity  were observed  for  all antimycotics  in this  study.  Inaccuracy  and  imprecision  of all
quality  controls  were  consistently  below  ± 12.6%  and  ± 8.1%,  respectively.  Quantification  results  were  in
agreement  with  an IVD  LC–MS/MS  method.
Conclusion: HRMS  was shown  to be  suitable  for TDM  of small  molecules  when  compared  to tandem  mass
spectrometry.  The  novel  HRMS  method  is  quickly  installed  and  may  be a robust  and  reliable  tool  for
routine  TDM  of antimycotics  in  clinical  laboratories.
©  2019  Elsevier  B.V.  All  rights  reserved.. Introduction
Invasive fungal infections by Candida, Aspergilli and Cryptococci
pecies are a leading cause of morbidity and mortality in patients
ith compromised immunity [1]. Invasive pulmonary diseases
aused by Aspergillus spp. are still associated with high mortality
ates up to 82% [2]. Early diagnosis, pathogen identification and
herapy initiation with appropriate antimycotic drugs are of upper-
ost importance for therapeutic success. However, in addition to
mmune-compromising conditions, altered pharmacokinetic vari-
∗ Corresponding author at: Institute of Laboratory Medicine, University Hospital,
MU  Munich, Marchioninistr. 15, 81377 Munich, Germany.
E-mail address: carina.schuster@med.uni-muenchen.de (C. Schuster).
1 Both authors contributed equally to this work and should therefore be both
onsidered  to be first authors.
ttps://doi.org/10.1016/j.jpba.2019.01.038
731-7085/© 2019 Elsevier B.V. All rights reserved.abilities with inadequate antimicrobial exposure at the site of
infection and drug interactions are contributing to poor prognosis
in critically ill patients [3,4]. Therapeutic drug monitoring (TDM)
of antimicrobials is therefore helpful to guide therapy in these vul-
nerable patients [5–7].
Several  systemic antimicrobial drugs are routinely administered
for severe invasive fungal infections such as azole antimycotics
or echinocandins. Quantification of these analytes is mainly
conducted using LC with UV detection (LC-UV) or LC-mass spec-
trometry (LC–MS) [8–14]. Although mass spectrometers have high
purchasing and maintenance costs, LC–MS assays are generally
favored over LC-UV analyses in several respects. Usage of MS-
detection provides a high degree of selectivity and sensitivity,
especially when samples from patients receiving extensive co-
medication are analyzed. In addition LC–MS analysis can be scaled
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p in simpler fashion to simultaneous quantification of many small
olecules and their metabolites in a single analytical run [15–17].
Orbitrap high resolution mass spectrometry (HRMS) analysis is
ecognized as an adequate technology for protein and metabolic
rofiling due to the enormous output of high resolution spectral
ata. However, mass spectrometry based small molecule TDM is
o far the domain of tandem mass spectrometry (MS/MS) [18–20].
hether Oribtrap-HRMS with its analytical features is also appli-
able for the quantitative analysis of small molecules, such as
nti-infective drugs, remains a subject of ongoing research [21,22].
ven though, LC–MS/MS methods were published for simultane-
us quantification of azole antifungals and some echinocandins
11,14,23], to our knowledge no LC-HRMS method which addresses
he previously mentioned 11 antimycotics was published yet. The
ain goal of the present study was therefore to develop a quanti-
ative antimycotics LC-HRMS test procedure and to compare it to
 routine IVD LC–MS/MS assay. Accordingly, the LC-HRMS method
n this study was implemented using commercially available com-
onents from an antimycotics TDM IVD kit.
. Materials and methods
.1.  Chemicals and reagents
The  optimization-mix 1 and 2 (containing different amounts
f analytes), the calibrators and the quality controls (QC) sets
ontaining 5-flucytosine (5-FC), amphotericin B (AM-B), anidula-
ungin (ANF), fluconazole (FCZ), isavuconazole (IVZ), itraconazole
ITZ), ketoconazole (KTZ), micafungin (MCF), OH-itraconazole
OH-ITZ), posaconazole (PSZ), voriconazole (VRZ) and the corre-
ponding isotope labelled internal standards 13C15N2-5-fluyctosine
13C15N2-5-FC), d4-fluconazole (d4-FCZ), 13Cd4-isavuconazole
13Cd4-IVZ), d5-itraconazole (d5-ITZ), d8-ketoconazole (d8-KTZ),
5−OH-itraconazole (d5−OH-ITZ), d4-posaconazole (d4-PSZ), d3-
oriconazole (d3-VRZ), as well as the precipitation reagent
precipitant P) are part of the LC–MS/MS ClinMass® TDM kit system
hat was obtained from RECIPE (Munich, Germany). Furthermore
 neat 5-FC (1.14 mg/mL) in absolute methanol was  provided
y RECIPE (Munich, Germany). Missing isotope labelled inter-
al standards 13C6-micafungin (13C6-MCF) and 13C6-anidulafungin
13C6-ANF) were purchased from Alsachim (Illkirch-Graffenstaden,
rance). The isotope labelled internal standard d3-amphotericin
 (d3-AM-B) was from Toronto Research Chemicals (North York,
anada). Drug-free serum was purchased from the blood donation
ervice of the Bavarian Red Cross (Wiesentheid, Germany).
Water, acetonitrile, methanol and formic acid 99% (each HPLC
rade) were obtained from Biosolve-chemicals (Dieuze, France).
mmonium acetate (HPLC grade) was purchased from Sigma-
ldrich (Missouri, USA). Ammonia solution 32% was from Merck
Massachusetts, USA). All chemicals were of the highest purity
vailable from commercial providers.
.2. Calibrators, quality control samples and internal standard
olution
Calibrators, quality controls (QC) and internal standard (ISTD)
olutions were prepared according to the manufacturerś instruc-
ions: Calibrator and QC lyophilisates provided in vials by the
anufacturer were directly re-suspended in 1.0 ml  water and
ixed for 15 min  at room temperature (RT) using a vortex shaker
IKA, Staufen, Germany). The IVD kit ISTD solution was prepared by
dding 5.0 ml  precipitant P, followed by solubilization for 15 min
t RT using an ultrasonic bath. The missing ISTD of ANF, AM-B and
CF  were dissolved in methanol and added to IVD kit precipita-
ion reagent P (1:8 v/v) directly before sample preparation. Final Biomedical Analysis 166 (2019) 398–405 399
concentrations  were 7.0 mg/L 13C15N2-5-FC, 0.80 mg/L d3-AM-B,
1.6 mg/L 13C6-ANF, 2.1 mg/L d4-FCZ, 1.4 mg/L 13Cd4-IVZ, 0.52 mg/L
d5-ITZ, 1.5 mg/L d8-KTZ, 4.0 mg/L 13C6-MCF, 0.66 mg/L d5−OH-ITZ,
0.70 mg/L d4-PSZ, 0.87 mg/L d3-VRZ. For simplicity the precipi-
tation reagent including all ISTD is referred to as “precipitation
mix”.
The kit contained 3 calibrator levels and 2 QC levels. To obtain
6 different calibrator levels the high and low level calibrator level
were diluted 1.5-fold and the medium calibrator level was  diluted
2.5-fold with drug-free serum, respectively. The lower QC level
from the kit was diluted with drug-free serum (1:3 v/v) to obtain
concentrations within 3-fold of the concentration of the lowest
limit of quantification (LLOQ) (QC 1). For simplicity calibrators and
QCs are named numeric Cal 1 - Cal 6 and QC 1 - QC 3. Final concentra-
tions are displayed in Table 1. All calibrators and QCs were aliquoted
to 50 L and stored at −20 ◦C, according to the kit manufacturerś
instructions.
2.3. Sample preparation
First,  100 L precipitation mix, containing all internal standards
for the analytes in this study, were added to 50 L of Calibrator, QC
or serum sample. The samples were vigorously mixed for 5 min  at
RT using a Thermomixer (Eppendorf, Hamburg, Germany). After
centrifugation for 5 min  (15 ◦C, 21,255 g) the supernatants were
transferred into a glass vial with micro insert (Chromatographie
Handel Müller, Fridolfing, Germany) and placed into the autosam-
pler ready for injection.
2.4.  Method development
According  to the manufacturerś kit instructions internal stan-
dards were dissolved in precipitant P. The ISTD vial from
manufacturerś kit included corresponding isotope labelled analogs
of all analytes except for AM-B, ANF and MCF. As a consequence
these missing ISTD were supplemented to the IVD kit ISTD solution
giving the final precipitation mix  (see chapter 2.2).
To  separate all antimycotics within a single chromatographic
run  usage of a turbulent flow technique extraction column with
mixed-phase properties was necessary. Separation of all analytes
wasnt́ feasible by four tested silica or polymer based extrac-
tion columns exhibiting only reversed-phase properties. Due to
reversed phase and cationic-exchange properties of the extrac-
tion column all analytes could be retained and concentrated before
analytical separation, even the most challenging and small analyte
5-flucytosine.
The usage of a mixed-phase extraction column needed adjust-
ment of mobile phases: Mobile phase C was  used to load the
extraction column with the analytes providing acidic conditions.
Buffer wasnt́ used to guarantee the absence of ammonium ions,
taking into account the cationic exchange mode. After the load-
ing phase the loop was  included with a mixture of mobile phase
B1 and D to elute the analytes using basic conditions with ammo-
nium acetate buffer and subsequently to re-equilibrate the ion
exchanger. To elute all analytes it was necessary to increase the
ammonia content to 2% since complete elution was not possi-
ble with less ammonia. Only a small amount of ammonia (0.1%
ammonia solution) was added to mobile phase D to change
the pH to basic conditions but still preserve the system from
too much ammonia. In summary mixed-phase Cyclone MCX-2
(0.5 x 50 mm)  column in combination with mobile phases C: water-
formic acid (99.8:0.2 v/v), B1: water-acetonitrile-ammonium
acetate (500 mM)-ammonia solution (32%) (5:92:1:2 v/v/v/v) and
D: water-ammonium acetate (500 mM)-ammonia solution (32%)
(98.9:0.1:1 v/v/v) were used.
32
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Table 1
Calibrator (Cal) and quality control sample (QC) concentrations [mg/L] for the antimycotics in this study.
Analyte Cal 1* Cal 2 Cal 3** Cal 4 Cal 5* Cal 6 QC 1*** QC  2 QC 3
5-Flucytosine 3.41 5.12 15.9 39.7 78.0 117 7.23 21.7 50.9
Amphotericin B 0.056 0.084 0.688 1.72 3.49 5.23 0.288 0.864 2.59
Anidulafungin 0.307 0.461 1.27 3.17 5.99 8.98 0.607 1.82 4.11
Fluconazole  0.376 0.564 1.66 4.14 8.40 12.6 0.763 2.29 5.40
Isavuconazole 0.321 0.482 1.40 3.49 7.07 10.6 0.640 1.92 4.55
Itraconazole  0.089 0.133 0.382 0.955 1.96 2.94 0.176 0.528 1.26
Ketoconazole 0.271 0.406 1.16 2.89 5.56 8.34 0.543 1.63 3.68
Micafungin  1.41 2.12 5.96 14.9 30.9 46.3 2.75 8.25 19.1
OH-Itraconazole 0.109 0.164 0.476 1.19 2.40 3.60 0.218 0.654 1.56
Posaconazole 0.155 0.232 0.672 1.68 3.34 5.01 0.303 0.910 2.18
Voriconazole 0.177 0.265 0.772 1.93 3.93 5.90 0.357 1.07 2.53
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* 1.5× dilution of Cal 2/Cal 6 from the kit.
** 2.5× dilution of Cal 4 from the kit.
*** 3× dilution of QC 2 from the kit.
.5. Liquid chromatography-high resolution mass spectrometry
onditions
Chromatography was performed on a Thermo Scientific Ulti-
ate 3000 system (Sunnyvale, CA, USA) provided with a quaternary
S pump for online SPE (loading pump) and a binary RS pump
or analytical separation (eluting pump) with 2 six-port switching
alves. The LC system was coupled to a Thermo Scientific Q Exac-
ive Focus Orbitrap mass spectrometer. The Thermo Scientific CTC
TS PAL autosampler was  kept at 10 ◦C, the injection volume was
 L.
Online  sample extraction was performed on a mixed-phase
roperties Cyclone MCX-2 (0.5 x 50 mm)  column from Thermo Sci-
ntific. The analytes in this study were then separated on a C18
ypersil GOLD (50 x 2.1 mm,  1.9 m)  column (Thermo Scientific)
hat was kept at 30 ◦C. Instrument controlling, data acquisi-
ion and processing were performed using the Tracefinder 4.1
oftware (Thermo Scientific). Schematic representation of the
alve-switching and corresponding chromatographic gradients is
iven in Fig. 1. The total run time was 4.0 min.
Optimized parameters of the HRMS system using optimization-
ix 1 were: sheath gas and auxiliary gas flow rate 50 AU and 15 AU
espectively, spray voltage 3.50 kV, S-lens 85.0 V, capillary and aux-
liary gas heater temperature 350 ◦C and 400 ◦C respectively. The
luate was analyzed in full MS  mode from m/z  110–1300 with a
esolution of 70,000 (FWHM) and an automatic gain control (AGC)
arget of 1e6 in positive electrospray ionization (ESI+) mode. The
aximum injection time was 50 ms  and mass tolerance was set
o 5 ppm. Analytes and internal standards with respective m/z and
etention times are shown in Table 2.
.6. Method validation
Assay  validation was performed on the basis of the Guideline
f bioanalytical method validation from the European Medicines
gency (EMA), 21 July 2011 [24]. The method was  evaluated
egarding calibration curve, inaccuracy, imprecision, limits of quan-
ification, carry-over, dilution integrity, matrix effect, selectivity
nd stability.
.6.1. Calibration curve
The  manufacturerś antimycotic kit contains 3 calibrators cov-
ring the clinically relevant range from sub-therapeutic to toxic
oncentrations. Three calibrators were introduced by dilution of
he kit calibrators using drug-free serum as described in section
.2.
All calibrators were processed together with a blank (serum
ithout analyte and ISTD) and zero sample (serum without analyte,
ut added ISTD). According to the EMA  guideline back calculatedconcentrations of all calibrators should be within ±15% of the nomi-
nal value, except for the LLOQ (calibrator 1), which should be within
±20%. The calibration curve parameters were: curve type: linear;
origin: ignore; weighting: 1/X.
2.6.2. Limits of quantification
According  to the EMA  guideline the lower limit of quantification
(LLOQ) was defined as the lowest calibrator with a signal-to-noise
ratio ≥ 5 and imprecision/inaccuracy ≤20%. The LLOQ was  prepared
by 1.5-fold dilution of the lowest calibrator level of the antimycotics
TDM IVD kit (see section 2.2). The upper limit of quantification
(ULOQ) was  defined as the highest assay calibrator.
2.6.3. Inaccuracy and imprecision
Inaccuracy  and imprecision were tested using calibrator 1
(LLOQ) and QC samples 1–3. Within-run inaccuracy and impre-
cision were determined by replicate analysis of 5 individually
prepared QCs. Between-run inaccuracy and imprecision were eval-
uated by analyzing 5 individually prepared QC samples per day, on
3 different days. Mean back calculated concentrations of all QCs
should be within ±15% of the nominal value, except for the LLOQ
where it should be within ±20%.
2.6.4. Carry-over
Carry-over was investigated by injecting blank serum samples
(without the analytes in this study and ISTD) from different donors
(n = 8) after the highest calibrator (ULOQ). According to the EMA
guideline the peak area in the drug-free serum sample should not
exceed 20% of the LLOQ peak area and 5% of the ISTD peak area.
2.6.5.  Matrix effect
Matrix  effects were tested by adding the analytes at 3 differ-
ent concentration levels (using optimization-mix 2 and the 5-FC
solution) to drug-free serum samples from different donors (n = 6)
and to absolute methanol. After sample extraction the matrix factor
(MF) was calculated for each analyte and ISTD forming the ratio of
the peak area in presence of the matrix and the peak area in absence
of the matrix. The ISTD normalized matrix factor was calculated as
the ratio of the analyte MF  and the MF  of the corresponding ISTD.
The coefficient of variation (CV) of the ISTD normalized MF  should
not exceed 15%.
To  additionally evaluate potential matrix effects a post-column
infusion experiment was  performed according to Bonfiglio et al.
[25]. The neat IVD kit optimization-mix 1, containing all analytes
with a concentration of 4 mg/L in methanol, was continuously
infused into the HRMS using a T-piece and a syringe pump while
processed blank drug-free sera were injected to the chromato-
graphic system. Corresponding chromatograms were compared to
the chromatogram obtained by injection of absolute methanol.
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Fig. 1. (A) Switching of valves (1) Loading and extraction step: 5 L sample was loaded onto the extraction column with mobile phase C. Interfering non-retained serum
components were directed into waste. At the same time the analytical column was equilibrated with mobile phase A and B2. (2) Transfer step: After switching of valves and
inclusion of the loop, containing mobile phase B1 and D the analytes were eluted from the extraction column by backflush and transferred onto the analytical column. To
compensate the flow from the extraction column to the analytical column the flow rate of the eluting pump was reduced accordingly. (3) Analytical separation step: After
re-switching of the valves, the analytes were separated on the analytical column using the gradient shown in Fig. 1B. Meanwhile the extraction column was washed with
mobile phase B1 and the loop was filled with conditions mentioned previously. Solvents from the extraction column were sent to waste again. (B) Corresponding solvent flow
rates  of the automated online extraction and analytical separation. (A): water-ammonium acetate (500 mM)-formic acid (98.9:0.1:1 v/v/v), B1: water-acetonitrile-ammonium
acetate  (500 mM)-ammonia solution (32%) (5:92:1:2 v/v/v/v), B2: water-acetonitrile-ammonium acetate (500 mM)-formic acid (5:93.9:1:0.1 v/v/v/v), C: water-formic acid
(99.8:0.2  v/v), D: water-ammonium acetate (500 mM)-ammonia solution (32%) (98.9:0.1:1 v/v/v).
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Fig. 1. (Continued)
Table 2
Retention times and m/z of analytes and corresponding isotope labelled internal standards.
Analyte [M+H] r.t. (min) Corresponding internal standard [M+H] r.t. (min)
5-flucytosine 130.0411 1.10 13C15N2-5-fluycotsine 133.0385 1.10
Amphotericin B 906.4815* 2.06 d3-amphotericin B 923.5170* 2.06
Anidulafungin 1140.5136 2.31 13C6-anidulafungin 1146.5337 2.31
Fluconazole  307.1113 1.92 d4-fluconazole 311.1364 1.92
Isavuconazole 438.1194 2.36 13Cd4-isavuconazole 443.1479 2.36
Itraconazole  705.2466 2.44 d5-itraconazole 710.2780 2.44
Ketoconazole 531.1560 2.10 d8-ketoconazole 539.2062 2.10
Micafungin  1270.4456 2.22 13C6-micafungin 1276.4658 2.22
OH-itraconazole 721.2414 2.31 d5-OH-itraconazole 726.2728 2.31
Posaconazole 701.3369 2.29 d4-posaconazole 705.3620 2.29
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Voriconazole  350.1223 2.18 
* [M-H+H2O].
reak downs of analyte signal intensities would indicate relevant
on suppression.
.6.6. Selectivity
To  investigate selectivity, leftover sera from intensive care unit
ICU) patients (n = 18), non-ICU patients (n = 40) and various TDM
anel QCs from the clinical routine laboratory (n = 8), not includ-
ng the antimycotics in this project, were analyzed. Especially
CU patients received a broad range of medications in therapeutic
egimen, including analgesics, anaesthetics, antibiotics, antide-
ressants, antivirals, anticoagulants, antiemetics, cardiovascular
rugs, hypnotics and sedatives. Absence of interfering substances
as accepted if the response at respective analytical retention
imes was ≤ 20% of the LLOQ and ≤5% for the ISTD.
.6.7. Stability
Stability was tested using QC samples 1–3 that were stored
p to 6 h at RT and at 4 ◦C, up to 5 weeks at −20 ◦C and −80 ◦C.
utosampler stability was tested up to 24 h. Freeze-thaw stabil-
ty was determined in 3 cycles at −20 ◦C and −80 ◦C (freeze time >
2 h, thawing at RT). Stored QC samples were analyzed using freshly
repared calibration samples. According to the EMA  guideline sta-
ility is given if mean concentration changes are within ± 15% of
he nominal concentration.
.6.8.  Dilution integrity
To  test dilution integrity drug-free serum samples (n = 5) were
piked with an analyte concentration approximately 50% above the
LOQ and then diluted 5-fold with drug-free serum. The measured
oncentration was back calculated and compared to the nominal
oncentration. Inaccuracy and imprecision should not exceed ±
5%..6.9. Comparison commercial kit and extended kit
To  meet the EMA  guideline requirements all calibrator levels
nd 1 QC level were diluted to extend the number of calibrators andvoriconazole 353.1411 2.18
QCs (see section 2.2). Quantification conditions using 3 calibrator
levels and 2 QCs as suggested by the kit manufacturer were com-
pared to a calibration curve generated using 6 calibrators and 3 QCs.
Correlation coefficients (R2) of the calibration curves as well as inac-
curacy and imprecision of QCs were then compared to each other.
An aberration of these parameters between 6/3 calibrators/QCs and
3/2 calibrators/QCs would indicate that usage of 6 calibrator levels
and 3 QCs is more reliable when assessing unknown samples.
2.6.10.  Comparison of LC–MS/MS and LC-HRMS measurement
Analytical performance of the LC-HRMS method developed in
this study was compared to a LC–MS/MS IVD Kit (Chromsystems,
Gräfelfing, Germany) by replicate analysis of leftover routine TDM
samples including ITZ, OH-ITZ, PSZ and VRZ.
Both methods had very similar sample clean-up with protein
precipitation, but the chromatographic separation and quantifica-
tion approaches differed significantly (usage of the exact analyte
mass in HRMS vs. parent → daughter transitions in tandem MS).
Only patient samples with concentrations within the calibration
ranges of both assays were included in the comparative analysis.
3.  Results
3.1. Method validation
3.1.1.  Calibration curve
The  calibration curve was generated using 6 calibrators with
a linear regression model and weighting factor 1/X. The linearity
of the method could be shown over the whole calibration range
with R2 > 0.995 for all analytes. A representative analytical chro-
matogram is shown in Fig. 2.3.1.2. Lower limit of quantification (LLOQ)
The LLOQ signal-to-noise ratio of all analytes was at least ≥ x7
when compared to the blank samples at respective antimycotic
retention times. For back calculated LLOQ concentrations both
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Fig. 2. Representative chromatograms of analytes (calib
etween- and within-run inaccuracy and imprecision were ≤4.6%
nd ≤ 16.6%, respectively (see Table 3).
.1.3. Inaccuracy and imprecision
For  all analytes within-run inaccuracy was  ≤12.0%, within-
un imprecision was ≤8.1%, between-run inaccuracy was ≤9.0%
nd between-run imprecision was ≤7.1% in QC samples 1–3. The
espective results are summarized in Table 3. concentration). Retention times are shown in minutes.
3.1.4. Carry-over
Peak areas in 8 different drug-free serum samples injected after
a highest calibrator sample were consistently below 20% of the
LLOQ for all analytes and below 5% for the respective ISTD. The
highest peak area of all analytes was  12.7% of the LLOQ and 1.1% of
the ISTD, respectively.
36
404 C. Schuster et al. / Journal of Pharmaceutical and Biomedical Analysis 166 (2019) 398–405
Table 3
Mean  results for inaccuracy and imprecision of the LLOQ (= Cal 1) and QCs. calculated using 6 calibrator levels.
5-FC AM-B ANF FCZ IVZ ITZ KTZ MCF  OH-ITZ PSZ VRZ
Within-run inaccuracy (run 1) (n = 5) [%]
LLOQ −0.18 4.64 2.28 −1.12 −0.75 0.45 1.33 4.18 0.55 0.26 0.34
QC  1 3.06 −6.81 9.79 4.95 5.69 4.89 1.73 3.25 1.74 4.69 2.97
QC  2 −2.31 −8.38 −11.99 0.06 −0.53 −3.98 −6.87 −8.54 −3.33 −1.49 −1.44
QC  3 −1.57 −1.37 −0.59 0.92 −0.80 −2.89 −1.68 −4.38 −1.83 −0.68 −0.23
Between-run  inaccuracy (n = 15) [%]
LLOQ  −0.31 3.33 2.52 −0.76 −0.75 −0.15 0.71 3.95 −0.43 0.56 0.08
QC  1 2.43 −7.99 3.76 3.23 4.32 2.46 0.16 −2.23 2.54 1.28 2.00
QC  2 −2.63 −7.45 −8.96 −1.11 −0.60 −2.65 −4.99 −7.39 −1.92 −0.65 −1.60
QC  3 −2.17 2.62 −3.92 −0.85 −1.33 −3.29 −1.82 −2.97 −2.12 −1.72 −1.76
Within-run  imprecision (run 1) (n = 5) [%]
LLOQ 3.05 11.86 12.10 1.39 1.76 1.87 1.20 16.57 2.29 2.35 1.62
QC  1 2.26 3.07 5.99 2.49 2.01 1.98 2.42 8.09 1.73 2.39 2.18
QC  2 1.58 5.65 2.28 1.66 0.81 1.40 1.07 7.66 1.42 0.61 1.33
QC  3 0.37 3.33 3.41 1.52 0.75 0.81 0.34 4.16 1.43 0.61 0.59
Between-run  imprecision (n = 15) [%]
LLOQ 2.78 11.40 8.42 1.98 1.66 3.58 1.79 12.57 3.30 2.95 2.25
QC  1 2.96 6.58 6.87 2.17 2.06 4.27 4.04 6.85 3.07 5.02 2.30
QC  2 3.27 4.79 4.79 3.03 3.19 2.07 2.04 5.98 4.44 1.91 3.59
QC  3 1.97 7.09 6.06 3.16 1.39 2.94 1.97 7.12 2.38 3.21 2.35
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LOQ: lower limit of quantification. QC: Quality control. 5-FC: 5-flucytosine. AM-B: 
ole.  KTZ: ketoconazole. MCF: micafungin. OH-ITZ: OH-itraconazole. PSZ: posacona
.1.5. Matrix effect
The  post column infusion experiment did not indicate any rele-
ant matrix.
Evaluation of matrix effects according to the EMA  guideline
howed constant compensation of potential matrix effects by the
STD for all analytes at 3 tested concentration levels. ISTD normal-
zed matrix factors were as follows: 102.3% 5-FC, 103.7% AM-B,
8.6% ANF, 101.8% FCZ, 100.5% IVZ, 99.0% ITZ, 101.6% KTZ, 93.5%
CF, 99.1% OH-ITZ, 98.2% PSZ and 100.4% VRZ. The variation coef-
cients of the ISTD normalized MF  for all analytes was ≤ 9.2% and
herefore complied with the EMA  guideline requirements.
.1.6. Selectivity
The  method showed excellent selectivity where the maximum
esponse was ≤3.0% of the LLOQ for all analytes and ≤0.38% for
he ISTD in all ICU, non-ICU patient samples and assayed clinical
aboratory routine TDM quality controls.
.1.7. Stability
All  analytes were stable for at least 5 weeks at −20 ◦C and −80 ◦C.
reeze-thaw stability was given for all analytes, except for ampho-
ericin B where QC 1 slightly exceeded the EMA  guideline criteria
ith a deviation of -16.3% for the 3rd freeze-thaw cycle.
Benchtop stability (up to 6 h at RT) was given for all analytes
xcept for anidulafungin where QC 2 and QC 3 showed a devia-
ion of -16.6% and -18.2% after 4 h and -25.2% and -21.4% after 6 h,
espectively. Additionally, micafungin did not meet the require-
ents with a deviation of -18.5% in QC 2 after 6 h at RT. All analytes
ere stable during 6 h at 4 ◦C. Autosampler stability was  proven for
ll analytes within 24 h at 10 ◦C.
.1.8. Dilution integrity
Dilution  integrity was shown for all analytes. Inaccuracy ranged
rom 9.6% to 13.1% and imprecision ranged from 1.1% to 4.1%. How-
ver, amphotericin B did not meet the suggested EMA  guideline
equirements of inaccuracy and imprecision ranging ±15% where
naccuracy was -20.5% and imprecision 16.5%.
.2. Method comparison.2.1.  Commercial kit and extended kit
To evaluate potential impairments using 3 instead of 6 calibra-
ors three calibration curves and respective QCs were compared.otericin B. ANF: anidulafungin. FCZ: fluconazole. IVZ: isavucaonazole. ITZ: itracona-
RZ: voriconazole.
Linearity  was  shown for all calibration ranges with R2 > 0.995 using
6 calibrators and R2 > 0.997 using 3 calibrators. Additionally calcu-
lated % CV of all R2 values was  < 0.2% (n = 6). Inaccuracy of QC 2 and
QC 3 was ≤ 13.9% calculated with 6 calibrators and ≤ 12.9% calcu-
lated with 3 calibrators. Imprecision was  ≤7.8% and ≤9.2% for QC 2
and ≤8.1% and ≤11.7% for QC 3 calculated using a calibration curve
with 6 calibrators and 3 calibrators respectively.
3.2.2. LC-HRMS and LC–MS/MS
Comparable  results were obtained between the HRMS and
MS/MS method when assaying anonymized trough serum samples
from patient receiving treatment with ITZ, PSZ and VRZ according
to clinical guidelines. The mean difference was  1.2% (n = 14), 2.5%
(n = 15), 13.2% (n = 10) and 6.8% (n = 8) for ITZ, OH-ITZ, PSZ and VRZ
respectively.
4. Discussion
The developed method provides rapid sample preparation, fol-
lowed by clean-up with a mixed-phase extraction column in order
to minimize matrix interference. The cationic exchange mode of
this column mixed with reversed phase properties required mobile
phases with different amounts of acidic and basic components,
which made concentration and purification of all analytes possible.
Usage of commercially available kit components supported easy
and rapid set up of the described method on an Orbitrap-HRMS,
although the kit was  designed for MS/MS.
Notably 5-fluyctosine showed highest deviations regarding
carry-over (≤12.7%), which is still below the EMA  guideline require-
ments of ≤20%. This can be due to its early elution where residual
matrix components can co-elute, since 5-flucytosine is a very small
and challenging analyte with m/z 130.0411. These findings indicate
that mere protein precipitation without on-line sample extraction
or other secondary sample preparations wouldnt́ sufficiently elim-
inate relevant matrix effects. After optimization of the extraction
protocol HRMS analysis showed good LLOQ results (inaccuracy ≤
4.6%, imprecision ≤16.6%), insignificant carry-over, as well as excel-
lent selectivity for all analytes in this study.
Concentrations of antimycotics above the calibration curve can
be reliably quantified by 5× dilution using drug-free serum with
exception of amphotericin B. Yet, observed deviations may  result
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2011, accessed August 2018 http://www.ema.europa.eu/docs/en GB/
document library/Scientific guideline/2011/08/WC500109686.pdf.
[25]  R. Bonfiglio, et al., The effects of sample preparation methods on theC. Schuster et al. / Journal of Pharmaceutic
rom the instability of the analyte amphotericin B, especially when
amples are exposed to light during processing.
EMA guideline within-run and between-run inaccuracy and
mprecision requirements complied with all analytes. Furthermore
o relevant matrix effect was shown due to compensation by the
STD with a CV of the internal standard normalized matrix factor
9.2%.
Stability experiments showed good results when QCs were
tored at 4 ◦C, −20 ◦C and −80 ◦C or processed QCs were cooled
n the autosampler at 10 ◦C. Freeze-thaw stability was excellent for
ll analytes except of the 3rd cycle for amphotericin B, which could
gain be explained by its light instability. Problematic benchtop sta-
ility was proven for anidulafungin and micafungin after 4 h and 6 h
espectively. Therefore it would be reasonable to avoid freeze-thaw
ycles and long storage at room temperature by producing aliquots
nd keeping the benchtop sample preparation time as short as pos-
ible or storing samples at 4 ◦C with light protection until they are
rocessed.
The comparison of 3 calibrators, as suggested by the MS/MS
it manufacturer, against 6 calibrator levels showed that using 3
alibrators is sufficient to generate a calibration curve. No major
eviations could be observed regarding inaccuracy and imprecision
f QCs or correlation coefficient of the calibration curve. However,
wareness that no calibration curve can be generated is mandatory
f one calibrator out of three would be rejected from analysis.
Although a limited number of ITZ (including OH-ITZ), PSZ and
RZ samples were quantified with the clinical routine LC–MS/MS
ethod and the herein described LC-HRMS method, the measured
esults of both methods were comparable to each other with a
ercentage deviation ≤13.2%.
We believe that HRMS can be a feasible alternative for TDM
f small molecules besides MS/MS. Even though higher costs are
elated with Orbitrap HRMS the technology provides many advan-
ages. At first method development can be executed rapidly since
here is no need for time-consuming optimization of tuning param-
ters (e.g. collision energy of product ions) with Full MS  scan mode.
lso retrospective adding of analytes to an existing method is
racticable, as well as unknown screening of complex matrices.
urthermore usage of HRMS for protein and metabolomic analysis,
esides TDM is a common procedure. At last quantification of ana-
ytes or metabolites with very similar m/z  using HRMS is feasible
ithout extensive LC separation.
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3 Appendix 
3.1 List of abbreviations 
ADME  absorption, distribution, metabolism, excretion 
EMA  European Medicines Agency 
HRMS  high-resolution mass spectrometry 
ICU  intensive care unit 
LC-MS  isotope dilution liquid chromatography mass spectrometry 
MIC  minimal inhibitory concentration 
MRM  multiple reaction monitoring 
MS  mass spectrometry 
MS/MS  tandem mass spectrometry 
m/z  mass-to-charge ratio 
PD  pharmacodynamics 
PK  pharmacokinetics 
SIL-IS  stable isotopically labeled internal standard 
TDM  therapeutic drug monitoring  
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